Pyrrolidine derivatives and methods of use

Abstract

The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.

Description

[0001] Cross-references to related applications

[0002] This application claims priority and benefit to U.S. Provisional Patent Application No. 63 / 119,621, filed November 30, 2020, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] This disclosure relates to compounds and methods of using such compounds in therapies. This disclosure further relates to the use of the compounds described herein or pharmaceutical compositions thereof for the prevention and / or treatment of hyperproliferative disorders such as cancer. The compounds described herein or pharmaceutical compositions thereof may also be used to treat diseases or indications associated with VHL activity. Background Technology

[0004] There is a persistent need for small molecule compounds that can be used in therapies, such as for treating hyperproliferative disorders like cancer. Summary of the Invention

[0005] In one aspect, this disclosure relates to a compound of formula (I):

[0006]

[0007] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0008] I)L 1 -R 1 It is methyl;

[0009] L 2 For key or C 1-12 alkyl;

[0010] R 2 for

[0011] i)-OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears;

[0012] ii) 4- to 20-membered heterocyclic groups, optionally surrounded by one or more R groups. s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0013] iii) Mixed aromatic compounds ranging from 5 to 20 yuan, of which R 2 The 5- to 20-yuan heteroaryl group is substituted by one or more R s Replace; where R sEach time it appears, it is independently halogenated, C 1-12 alkyl;

[0014] iv)C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 Alkyl; or

[0015] L 2 -R 2 It is cyclopropyl;

[0016] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 alkyl;

[0017] R 1 for

[0018] i)-L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl;

[0019] ii)C 4-20 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl;

[0020] iii)C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl;

[0021] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more Rt Replace; where R t It is C independently each time it appears. 1-6 alkyl;

[0022] iv) 5 to 20 yuan of heteroaryl groups, optionally coated with one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl;

[0023] Where R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears;

[0024] v) A 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0025] Where R s C 1-6 Alkyl groups are optionally surrounded by one or more R t replace;

[0026] Where R t It is C independently each time it appears. 6-20 Aryl,

[0027] Where R s C 6-20 Alkyl groups are optionally surrounded by one or more R u replace;

[0028] Where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

[0029] In another aspect, this disclosure relates to pharmaceutical compositions comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutical salt thereof, and one or more pharmaceutical excipients.

[0030] In one aspect, this disclosure relates to a method of treating a disease or indication associated with VHL activity using a compound of formula (I), or one or more of the compounds described herein, or stereoisomers or tautomers thereof, or a pharmaceutical salt of any of the foregoing, or one or more of the pharmaceutical compositions described herein.

[0031] In a further aspect, this disclosure relates to methods for preventing or treating hyperproliferative disorders, anemia, or ischemia by administering to a subject in need one or more of the compounds described herein, or stereoisomers or tautomers thereof, or pharmaceutical salts of any of the foregoing, or one or more of the pharmaceutical compositions described herein. In some embodiments, the hyperproliferative disorder is cancer and the subject is a human being. In some embodiments, the hyperproliferative disorder is a solid tumor. In some such embodiments, the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

[0032] In another aspect, a compound of formula (II) is provided:

[0033]

[0034] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0035] I)L 1 -R 1 It is methyl;

[0036] L 2 For key or C 1-12 alkyl;

[0037] R 2 for

[0038] i)-OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears;

[0039] ii) 4- to 20-membered heterocyclic groups, optionally surrounded by one or more R groups. s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0040] iii) Mixed aromatic compounds ranging from 5 to 20 yuan, of which R 2 The 5- to 20-yuan heteroaryl group is affected by one or more R s Replace; where R s It is independently halogenated or C each time it appears. 1-12 alkyl;

[0041] iv)C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0042] v)-N(CH3)-C 6-20 Aryl;

[0043] iv)-C 6-20 aryl, optionally constituting one or more R s Replace; where R s It is C independently each time it appears. 1-6 Halogenated alkyl; or

[0044] L 2 -R 2 It is cyclopropyl;

[0045] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Pick

[0046] Generation; among which R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; R 1 for

[0047] i)-L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl;

[0048] ii)C 4-20 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl;

[0049] iii)C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl;

[0050] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more Rt Replace; where R t It is C independently each time it appears. 1-6 alkyl;

[0051] iv) 5 to 20 yuan of heteroaryl groups, optionally coated with one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl;

[0052] Where R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears; or

[0053] v) A 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0054] Where R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl,

[0055] Where R s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

[0056] It should be understood that any method of preparing or using compounds of formula (I) also applies to compounds of formula (II). Detailed Implementation

[0057] This disclosure relates to compounds and their pharmaceutical salts.

[0058] The subject matter disclosed herein will now be described more fully below. However, many modifications and other embodiments of the subject matter set forth herein will conceive by those skilled in the art, benefiting from the teachings set forth in the foregoing description, as applicable to the subject matter of this present disclosure. Therefore, it should be understood that the subject matter of this present disclosure is not limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. In other words, the subject matter described herein encompasses alternatives, modifications, and equivalents. If any of the incorporated documents, patents, and similar materials differ from or contradict this application, including but not limited to defined terminology, usage of terminology, described techniques, or similar content, this application shall prevail. Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains, and the term is applied in the context of its use in describing this disclosure. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit this disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety.

[0059] I. Definition

[0060] The term "group" refers to a component that is covalently bonded or connected to another component.

[0061] The term "covalent bond" or "covalent connection" refers to a chemical bond formed by sharing one or more pairs of electrons.

[0062] As used herein, unless otherwise defined in the claims, the term “optionally” means that the event described below may or may not occur, and includes both events that occur and events that do not occur.

[0063] As used herein, unless otherwise defined, the phrase “optionally substituted,” “substituted,” or variations thereof, means that the object is optionally substituted by one or more substituents (e.g., one, two, three, four, or five substituents), including multiple degrees of substitution. This phrase should not be construed as a repetition of the substitutions described and depicted herein.

[0064] As used herein, the term "alkyl" refers to a saturated straight-chain or branched monovalent hydrocarbon group (C1-C1) of any length having one to twelve carbon atoms. 12The alkyl group may optionally be independently substituted by one or more substituents described herein. In another embodiment, the alkyl group is one to eight carbon atoms (C1-C8), one to six carbon atoms (C1-C6), one to four carbon atoms (C1-C4), or one to three carbon atoms (C1-C3). Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, isopropyl, isopropyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, isobutyl, -CH2CH(CH3)2), 2-butyl (s-Bu) sec-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, tert-butyl, tert-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH2CH2CH3) 3) CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl 4-Methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 3-Methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-Methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-Dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-Dimethyl-2-butyl (-CH(CH3)C(CH3)3), 1-Heptyl and 1-Octyl, etc.

[0065] As used herein, the term "alkylene" refers to a saturated straight-chain or branched divalent hydrocarbon group (C1-C1) of any length having one to twelve carbon atoms. 12The alkylene group may optionally be independently substituted by one or more substituents described herein. In another embodiment, the alkylene group is one to eight carbon atoms (C1-C8), one to six carbon atoms (C1-C6), or one to four carbon atoms (C1-C4). Examples of alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), etc.

[0066] The terms "carbocyclic", "carbocyclic group", "carbocyclic ring", and "cycloalkyl" refer to monocyclic rings having 3 to 12 carbon atoms (C3-C4). 12 A monovalent, non-aromatic, saturated, or partially unsaturated ring of 7 to 12 carbon atoms, or as a polycyclic (e.g., bicyclic) ring. Bicyclic carbocyclic rings of 7 to 12 atoms can be arranged as, for example, bicyclic [4,5], [5,5], [5,6], or [6,6] systems, and bicyclic carbocyclic rings of 9 or 10 ring atoms can be arranged as bicyclic [5,6] or [6,6] systems, or as bridging systems, such as bicyclic [2.2.1]heptane, bicyclic [2.2.2]octane, and bicyclic [3.2.2]nonane. Polycyclic (e.g., bicyclic) rings that are generally fully saturated or partially unsaturated are encompassed within the definitions of the terms “carbocyclic,” “carbocyclic group,” “carbocyclic ring,” and “cycloalkyl,” including when one or more fused rings in the polycyclic ring are fully unsaturated (i.e., aromatic). Spirocyclic moieties are also included within the scope of this definition. Examples of monocyclic carbocyclic groups include, but are not limited to: cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, indenyl, dihydroindenyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthalene, etc. The carbocyclic group may optionally be independently substituted by one or more substituents described herein.

[0067] "Aryl" refers to a group of 6 to 20 carbon atoms (C6-C6) derived by removing a hydrogen atom from a single carbon atom in the parent aromatic ring system. 20 The aryl group is a monovalent aromatic hydrocarbon group. Some aryl groups are represented as "Ar" in the exemplary structures. Typical aryl groups include, but are not limited to, groups derived from benzene (phenyl), substituted benzene, naphthalene, anthracene, etc. The aryl group may optionally be independently substituted by one or more substituents described herein.

[0068] The terms “heterocycle,” “heterocyclic group,” and “heterocycle” are used interchangeably herein and refer to a saturated or partially unsaturated (i.e., having one or more double and / or triple bonds within a ring) carbocyclic group having 3 to about 20 ring atoms, wherein at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, and the remaining ring atoms are carbon, wherein one or more ring atoms are optionally and independently substituted by one or more substituents described herein. A heterocycle can be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S) or having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), for example: bicyclic [4,5], [5,5], [5,6], or [6,6] systems. Heterocyclic compounds are described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (WA Benjamin, New York, 1968), especially Chapters 1, 3, 4, 6, 7 and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), especially Volumes 13, 14, 16, 19 and 28; and J. Am. Chem. Soc. (1960) 82: 5566. “Heterocyclic group” also includes groups in which the heterocyclic group is fused with a saturated, partially unsaturated ring or an aromatic carbocyclic or heterocyclic ring. Examples of heterocyclic rings include, but are not limited to: morpholin-4-yl, piperidin-1-yl, piperazinyl, piperazin-4-yl-2-one, piperazin-4-yl-3-one, pyrrolidine-1-yl, thiomorpholin-4-yl, S-dioxothiomorpholin-4-yl, azoalkyl-1-yl, aziridine-1-yl, octahydropyridino[1,2-a]pyrazin-2-yl, [1,4]diazapine-1-yl, pyrrolylyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiopheneyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, aziridine-butyl, oxacyclobutyl, thiohexyl, homopiperidineyl, oxacyclohexyl, thiohexyl, oxacyclohexyl basalt, diazoxide Basic, sulfur-nitrogen The heterocyclic groups include 2-pyrrolinyl, 3-pyrrolinyl, dihydroindolyl, 2H-pyranyl, 4H-pyranyl, dioxalyl, 1,3-dioxapentyl, dihydropyrazolyl, dithienyl, dithiopentyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolinylimidazolinyl, imidazoalkyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 3H-indolylquinolinyl, and N-pyridylurea. Spirocyclic moieties are also included within the scope of this definition. Examples of heterocyclic groups in which two ring atoms are replaced by an oxygen (=O) moiety are pyrimidinone and 1,1-dioxo-thiomorpholinyl. The heterocyclic groups described herein may optionally be independently substituted by one or more of the substituents described herein.

[0069] The term "heteroaryl" refers to a monovalent aromatic group with a 5-, 6-, or 7-membered ring and comprising a fused ring system of 5 to 20 atoms (at least one of which is aromatic) containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups are pyridyl (including, for example, 2-hydroxypyridyl), imidazolyl, imidazopyridyl, 1-methyl-1H-benzo[d]imidazolium, [1,2,4]triazolo[1,5-a]pyridine, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thiophene, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, and pyrroleyl. Quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cenolinyl, indazoleyl, indolazinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purineyl, oxadiazolyl, thiadiazolyl, thiadiazolyl, furazolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzooxazolinyl, benzooxazolyl, quinazolinyl, quinoxolinyl, naphthidinyl, and furanpyridinyl. The heteroaryl group may optionally be independently substituted by one or more of the substituents described herein.

[0070] Where possible, the heterocyclic or heteroaryl group can be carbon-linked (carbon-dependent) or nitrogen-linked (nitrogen-dependent). For example, but not limitingly, the carbon-linked heterocyclic or heteroaryl group is bonded at the following positions: 2, 3, 4, 5, or 6 of pyridine; 3, 4, 5, or 6 of pyridazine; 2, 4, 5, or 6 of pyrimidine; 2, 3, 5, or 6 of pyrazine; 2, 3, 4, or 5 of furan, tetrahydrofuran, thifuran, thiophene, pyrrole, or tetrahydropyrrole ring; 2, 4, or 5 of oxazole, imidazole, or thiazole; 3, 4, or 5 of isoxazole, pyrazole, or isothiazole; 2 or 3 of aziridine; 2, 3, or 4 of azacyclobutane; 2, 3, 4, 5, 6, 7, or 8 of quinoline; or 1, 3, 4, 5, 6, 7, or 8 of isoquinoline.

[0071] For example, but not limitingly, the nitrogen-bonded heterocyclic or heteroaryl group is bonded at the following positions: 1 position of aziridine, aziridine, pyrrole, pyrrolidine, 2-pyrrololine, 3-pyrroleline, imidazole, imidazoleidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, dihydroindole, 1H-indazole; 2 position of isoindole or isodihydroindoline; 4 position of morpholine; and 9 position of carbazole or β-carbline.

[0072] The term "oxo" means "=O".

[0073] "Patient," "individual," or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the patient or individual or subject is a person. In some embodiments, the patient may be a "cancer patient," that is, a patient who has one or more symptoms of cancer or is at risk of developing one or more symptoms of cancer.

[0074] The terms “cancer” and “cancerous” refer to or describe a physiological condition in mammals that is typically characterized by uncontrolled cell growth / proliferation. A “tumor” contains one or more cancer cells.

[0075] As used herein, “treatment” (and its grammatical variations, such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of the individual being treated, and may be for prevention or in the course of clinicopathology. The desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and mitigating or improving prognosis. In some embodiments, the compounds and compositions of the subject matter described herein are used to delay the development of disease or slow its progression. In one embodiment, treatment is performed solely for prevention. In another embodiment, treatment is performed only during the clinicopathological process (i.e., not for prevention). In yet another embodiment, treatment is performed only during the clinicopathological process and in preventative cases.

[0076] The term "effective" is used to describe the amount of a compound, composition, or component that, when used within its intended use, achieves a desired therapeutic or preventative effect. The term "effective" includes other effective amount or effective concentration terms, including therapeutically effective amounts, which are further described or used in this application. As used herein, the term "therapeuticly effective amount" means any amount that results in the treatment of a disease, condition, or side effect, or a reduction in the rate of progression of a disease or condition, compared to a corresponding subject who did not receive that amount. The term also includes, within its scope, amounts that effectively enhance normal physiological function. For use in a therapy, a therapeutically effective amount of the compound of this disclosure, its stereoisomers or tautomers, or a pharmaceutical salt of any of the foregoing, may be administered as the original chemical. Additionally, the active ingredient may be present as a pharmaceutical composition.

[0077] The terms “pharmaceutical formulation” or “pharmaceutical composition” refer to a formulation in which the bioactive ingredient contained herein is in a form in which it is bioactively effective and does not contain any additional components that would have unacceptable toxicity to a subject to whom the formulation will be administered.

[0078] "Pharmaceutical excipients" refer to components in pharmaceutical preparations that are non-toxic to the subjects, excluding the active ingredient. Pharmaceutical excipients include, but are not limited to, buffers, carriers, stabilizers, or preservatives.

[0079] As used herein, the phrase "medicinal salt" refers to a medicinal organic or inorganic salt of a molecule. Exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, bisulfates, phosphates, acid phosphates, isonicotinates, lactates, salicylates, acid citrates, tartrates, oleates, tannates, pantothenates, hydrogen tartrates, ascorbic acid salts, succinates, maleates, gentianates, fumarates, gluconates, glucurons, saccharates, formates, benzoates, glutamates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, and bis(hydroxynaphthyl)ate (i.e., 1,1'-methylenebis-(2-hydroxy-3-naphthyl)ate). Medicinal salts may include another molecule, such as an acetate ion, a succinate ion, or other counterions. Counterions can be any organic or inorganic portion that stabilizes the charge on the parent compound. Furthermore, a medicinal salt may have more than one charged atom in its structure. An example where multiple charged atoms are part of a medicinal salt may have multiple counterions. Therefore, a medicinal salt may have one or more charged atoms and / or one or more counterions.

[0080] Other non-pharmaceutical salts can be used to prepare the compounds described herein and should be considered as a further aspect forming the subject matter. These salts, such as oxalic acid or trifluoroacetate, while not pharmaceutical in themselves, can be used to prepare intermediates for obtaining the compounds described herein and their pharmaceutical salts.

[0081] The term "stereoisomer" refers to compounds that have the same chemical composition but different spatial arrangements of atoms or groups.

[0082] "Diabeta-isomers" are stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diabeta-isomers have different physical properties, such as melting point, boiling point, spectral characteristics, and reactivity. Mixtures of diastereomers can be separated using high-resolution analytical procedures such as electrophoresis and chromatography.

[0083] "Enantiomers" refer to two stereoisomers of a compound, which are non-overlapping mirror images of each other.

[0084] The stereochemical definitions and conventions used in this article generally follow: SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994), John Wiley & Sons, Inc., New York. Many organic compounds exist in an optically active form, meaning they have the ability to rotate around the plane of polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule around its chiral center. The prefixes d and l or (+) and (-) are used to indicate the symbol for the rotation of a compound around plane-polarized light, where (-) or 1 indicates that the compound is levorotatory. Compounds with the prefix (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers can also be called enantiomers, and mixtures of such isomers are often referred to as enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may occur in a chemical reaction or process without stereoselectivity or stereospecificity. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two optically inactive enantiomers.

[0085] Unless otherwise stated, the term "compound" as used herein means any particular compound disclosed herein, including tautomers, regioisomers, geometric isomers, and stereoisomers where applicable, including optical isomers (enantiomers) and other stereoisomers (diastereomers), as well as pharmaceutical salts and derivatives thereof (including prodrug forms) where applicable. When used in its context, the term "compound" generally refers to a single compound, but may also include other compounds such as stereoisomers, regioisomers, and / or optical isomers (including racemic mixtures) and specific enantiomers or enantiomer-rich mixtures of the disclosed compounds. In this context, the term also refers to a prodrug form of a compound that has been modified to facilitate the administration and delivery of the compound to the active site. It should be noted that many substituents and associated variables are described in the description of the compounds of the present invention. Those skilled in the art will understand that the molecules described herein are stable compounds, as generally described below. When bonds are shown... In this context, both double bonds and single bonds are represented within the context of the compound shown. When a crossed double bond is shown... In this context, both the E and Z configurations are indicated within the context of the compound shown; and the compound may contain the E isomer, the Z isomer, or a mixture of both the E and Z isomers.

[0086] In some embodiments disclosed herein, certain groups (e.g., alkyl, alkenyl, ynyl, cycloalkyl, aryl, heteroaryl, or heterocyclic) are described as “substituted.” In some such embodiments, the “substituted” group may be substituted by 1, 2, 3, 4, 5, or more substituents, as indicated herein. In some embodiments, the alkyl, alkenyl, ynyl, cycloalkyl, aryl, heteroaryl, or heterocyclic group may be substituted by one or more substituents independently selected from, but not limited to, the following: alkyl, alkenyl, ynyl, cycloalkyl heterocyclic, aryl, heteroaryl, halogen (i.e., halogen), haloalkyl, oxo, OH, CN, -O-alkyl, S-alkyl, NH-alkyl, N(alkyl)2, O-cycloalkyl, S-cycloalkyl, NH-cycloalkyl, N(cycloalkyl)2, N(cycloalkyl)(alkyl), NH2, SH, SO2-alkyl, P(O)(O-alkyl)(alkyl), P(O)(O-alkyl)2, Si(OH)3 、Si(alkyl)3、Si(OH)(alkyl)2、CO-alkyl、CO2H、NO2、SF5、SO2NH-alkyl、SO2N(alkyl)2、SONH-alkyl、SON(alkyl)2、CONH-alkyl、CON(alkyl)2、N(alkyl)CONH(alkyl),N(alkyl)CON(alkyl)2、NHCONH(alkyl),NHCON(alkyl)2、NHCONH2、N(alkyl)SO2NH(alkyl),N(alkyl)SO2N(alkyl)2、NHSO2NH(alkyl),NHSO2N(alkyl)2 andNHSO2NH2.

[0087] Where numerical ranges are provided, it should be understood that, unless the context explicitly specifies otherwise (such as in the case of a group containing multiple carbon atoms, in which case the number of each carbon atom falling within the range is provided), every intermediate value between the upper and lower limits of the range and any other stated or intermediate value within the range, up to one-tenth of the unit of the lower limit, is covered within this disclosure. The upper and lower limits of these smaller ranges may be independently included within that smaller range and are also covered by this disclosure, subject to any explicitly excluded limitations within the specified range. Where the range includes one or two limits, the range excluding any one or both of those included limitations is also included in this disclosure.

[0088] Unless the context clearly specifies otherwise, the articles “a” and “an” as used herein and in the appended claims refer to one or more (i.e., at least one) of the grammatical objects of the article. By way of example, “an element” means one element or more elements.

[0089] In the claims and in the foregoing description, transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” and “constituting of” should be understood as open-ended, meaning including but not limited to. Only the transitional phrases “constituting of” and “constituting substantially of” should be closed or semi-closed transitional phrases, respectively, as described in Section 2111.03 of the U.S. Patent Examination Procedure Manual.

[0090] It should also be understood that, unless the context otherwise requires, in some methods described herein that involve more than one step or action, the order of the steps or actions of the method is not necessarily limited to the order in which the steps or actions of the method are stated.

[0091] II.Compounds

[0092] In one embodiment, this document provides a compound of formula (I):

[0093]

[0094] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0095] I)L 1 -R 1 It is methyl;

[0096] L 2 For key or C 1-12 alkyl;

[0097] R 2 for

[0098] i)-OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears;

[0099] ii) 4- to 20-membered heterocyclic groups, optionally surrounded by one or more R groups. s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0100] iii) Mixed aromatic compounds ranging from 5 to 20 yuan, of which R 2 The 5- to 20-yuan heteroaryl group is affected by one or more R s Replace; where R s Each time it appears, it is independently halogenated, C 1-12 alkyl;

[0101] iv)C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 Alkyl; or

[0102] L 2 -R 2 It is cyclopropyl;

[0103] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Pick

[0104] Generation; among which R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; R 1 for

[0105] i)-L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl;

[0106] ii)C4-20 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl;

[0107] iii)C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl;

[0108] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl;

[0109] iv) 5 to 20 yuan of heteroaryl groups, optionally coated with one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl;

[0110] Where R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears;

[0111] v) A 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0112] Where R s C 1-6 Alkyl groups are optionally surrounded by one or more R t replace;

[0113] Where R t It is C independently each time it appears. 6-20 Aryl, wherein R s C 6-20 Alkyl groups are optionally surrounded by one or more R u replace;

[0114] Where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

[0115] In some embodiments, the compound of formula (I) is a compound of formula (Ia):

[0116]

[0117] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0118] L 2 For key or C 1-12 Alkyl; and

[0119] R 2 for

[0120] i)-OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears;

[0121] ii) 4- to 20-membered heterocyclic groups, optionally surrounded by one or more R groups. s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0122] iii) Mixed aromatic compounds ranging from 5 to 20 yuan, of which R 2 The 5- to 20-yuan heteroaryl group is substituted by one or more R s Replace; where R s It is independently halogenated or C-type each time it appears. 1-12 alkyl;

[0123] iv)C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl.

[0124] In some embodiments, the compound of formula (I) is a compound of formula (Ib):

[0125]

[0126] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0127] L 1 For key or C 1-12 Alkyl; wherein L 1C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxyl C 1-6 Alkyl; and

[0128] and

[0129] R 1 for

[0130] i)-L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl;

[0131] ii)C 4-20 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl;

[0132] iii)C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl;

[0133] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl;

[0134] iv) 5 to 20 yuan of heteroaryl groups, optionally coated with one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl;

[0135] Where R s C 6-20 Aryl group is optionally bounded by one or more Rt Replace; where R t It is halogenated independently each time it appears;

[0136] v) A 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0137] Where R s C 1-6 Alkyl groups are optionally surrounded by one or more R t replace;

[0138] Where R t It is C independently each time it appears. 6-20 Aryl, wherein R s C 6-20 Alkyl groups are optionally surrounded by one or more R u replace;

[0139] Where R u It is independently halogenated or C each time it appears. 1-6 alkyl.

[0140] In some embodiments, the compound of formula (I) or the compound of formula (Ia) is a compound of formula (Ia-1) or (Ia-2):

[0141]

[0142] Where L 2 and R 2 As defined with respect to formula (I). In some embodiments, the compound is a compound of formula (Ia-1). In some embodiments, the compound is a compound of formula (Ia-2).

[0143] In some embodiments, the compound of formula (I) or formula (Ib) is a compound of formula (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), or (Ib-9):

[0144]

[0145] Where L 1 and R 1As defined with respect to formula (I). In some embodiments, the compound is a compound of formula (Ib-1). In some embodiments, the compound is a compound of formula (Ib-2). In some embodiments, the compound is a compound of formula (Ib-3). In some embodiments, the compound is a compound of formula (Ib-4). In some embodiments, the compound is a compound of formula (Ib-5). In some embodiments, the compound is a compound of formula (Ib-6). In some embodiments, the compound is a compound of formula (Ib-7). In some embodiments, the compound is a compound of formula (Ib-8). In some embodiments, the compound is a compound of formula (Ib-9).

[0146] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0147] L 1 -R 1 It is methyl;

[0148] L 2 For key or C 1-12 Alkyl; and

[0149] R 2 -OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears.

[0150] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 2 It is -O-C6 aryl, optionally substituted with one or more halogens. In some such embodiments, R 2 It is -O-C6 aryl, optionally substituted with one or more fluorinated groups. In some such embodiments, R 2 It is a -O-C6 aryl group that has been substituted with a fluorine molecule.

[0151] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0152] L 1 -R 1 It is methyl;

[0153] L 2 For key or C 1-12 Alkyl; and

[0154] R2 It is a 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl.

[0155] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 2 It is a 6-membered heterocyclic group, optionally surrounded by one or more -C(O)OC groups. 1-6 Alkyl substitution. In some embodiments, R 2 It is a 6-membered heterocyclic group, optionally substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 It is a 6-membered heterocyclic group substituted with a -C(O)O-CH3 group. In some embodiments, R 2 It is a 6-membered heterocyclic group containing 1 to 3 N heteroatoms, optionally bonded by one or more -C(O)OC groups. 1-6 Alkyl substitution. In some embodiments, R 2 It is a 6-membered heterocyclic group containing 1 to 3 N heteroatoms, optionally substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 It is a 6-membered heterocyclic group containing 1 to 3 N heteroatoms substituted with a -C(O)O-CH3 group. In some embodiments, R 2 for Optionally by one or more -C(O)OC 1-6 Alkyl substitution. In some embodiments, R 2 for Optionally replaced by one or more -C(O)O-CH3.

[0156] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0157] L 1 -R 1 It is methyl;

[0158] L 2 For key or C 1-12 Alkyl; and

[0159] R 2 It consists of 5 to 20 yuan of heteroaryl compounds, of which R 2 The 5- to 20-yuan heteroaryl group is substituted by one or more R s Replace; where R s It is independently halogenated or C each time it appears.1-12 alkyl.

[0160] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 2 For one or more R s Substituted 6- to 9-membered heteroaryl groups; of which R s It is independently halogenated or C-type each time it appears. 1-12 Alkyl group. In some embodiments, R 2 For being halogenated or C-shaped 1-12 Alkyl-substituted 6-membered heteroaryl groups. In some embodiments, R 2 It is a 6-membered heteroaryl group substituted with one or more fluorinated or C1 alkyl groups. In some embodiments, R 2 For compounds containing 1 to 3 N heteroatoms that have been halogenated or carbon-substituted with one or more C atoms 1-12 Alkyl-substituted 6-membered heteroaryl. In some embodiments, R 2 for Halogenated by one or more C 1-12 Alkyl substitution. In some embodiments, R 2 for It is substituted with one or more fluorinated or C1 alkyl groups. In some embodiments, R 2 For being halogenated or C-shaped 1-12 Alkyl-substituted 9-membered heteroaryl groups. In some embodiments, R 2 It is a 9-membered heteroaryl group substituted with one or more C1 alkyl groups. In some embodiments, R 2 For compounds containing 1 to 3 N heteroatoms that have been halogenated or carbon-substituted with one or more halogenated atoms 1-12 Alkyl-substituted 9-membered heteroaryl. In some embodiments, R 2 for Halogenated by one or more C 1-12 Alkyl substitution. In some embodiments, R 2 for It is substituted by one or more C1 alkyl groups.

[0161] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0162] L 1 -R 1 It is methyl;

[0163] L 2 For key or C 1-12 Alkyl; and

[0164] R2 C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl.

[0165] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 2 It is a C6 cycloalkyl group, optionally surrounded by one or more -C(O)OC 1-6 Alkyl substitution. In some embodiments, R 2 It is a C6 cycloalkyl group, optionally substituted with one or more -C(O)O-CH3 groups. In some embodiments, R 2 It is a C6 cycloalkyl group substituted with a -C(O)O-CH3.

[0166] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0167] L 2 -R 2 It is cyclopropyl;

[0168] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0169] R 1 -L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl.

[0170] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 1 -L3 -C6 aryl, L 3 It is O or C(O)NH, and -L 3 The C6 aryl group of the -C6 aryl group is optionally surrounded by one or more halogenated C6 groups. 1-6 Alkyl substitution. In some embodiments, L 3 For O. In some embodiments, L 3 For C(O)NH. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 It is O or C(O)NH, and -L 3 -The C6 aryl group is optionally substituted with one or more halo-C1 alkyl groups. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 It is O or C(O)NH, and -L 3 The C6 aryl group of the -C6 aryl group is optionally surrounded by one or more fluorinated C groups. 1-6 Alkyl substitution. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 It is O or C(O)NH, and -L 3 The C6 aryl group of the -C6 aryl group is optionally replaced by one or more -CF3 groups. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 It is O or C(O)NH, and -L 3 The C6 aryl group of the -C6 aryl group is replaced by a -CF3 group. In some embodiments, R 1 -L 3 -C6 aryl, where L 3 It is O or C(O)NH, and -L 3 The C6 aryl group of -C6 aryl is not substituted.

[0171] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0172] L 2 -R 2 It is cyclopropyl;

[0173] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R eIt is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0174] R 1 C 4-20 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl.

[0175] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 1 C 6-11 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some embodiments, R 1 It is a C6 cycloalkyl group, optionally surrounded by one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some such embodiments, R s Each time it appears, it is independently a 9-membered heteroaryl or S(O)C. 1-6 Alkyl group. In some such embodiments, R s Independently for each occurrence Or S(O)CH2CH3. In some embodiments, R 1 It is a C9 cycloalkyl group, optionally surrounded by one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some such embodiments, R s It is halogenated independently each time it occurs. In some such embodiments, R s Halogenation. In some embodiments, R 1 for Optionally by one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some such embodiments, R s It is halogenated independently each time it occurs. In some such embodiments, R sHalogenation. In some embodiments, R 1 C 11 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some such embodiments, R s It is halogenated independently each time it occurs. In some such embodiments, R s It is independently brominated each time it appears. In some embodiments, R 1 for Optionally by one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 Alkyl group. In some such embodiments, R s It is halogenated independently each time it occurs. In some such embodiments, R s It is brominated independently each time it appears.

[0176] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0177] L 2 -R 2 It is cyclopropyl;

[0178] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0179] R 1 C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl.

[0180] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more R t Replace; where R tIt is C independently each time it appears. 1-6 alkyl.

[0181] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 1 It is C6 aryl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or a 5- to 20-membered heteroaryl group, and R is present in the group. s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more R t Replace; where R t It is C independently each time it appears. 1-6 Alkyl group. In some embodiments, R1 is a C6 aryl group, optionally surrounded by one or more R groups. s Replace; where R s Each time it appears, it is independently fluorinated, brominated, or cyaninated.

[0182] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0183] L 2 -R 2 It is cyclopropyl;

[0184] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0185] R 1 It is a heteroaryl group ranging from 5 to 20 ppm, optionally surrounded by one or more R... s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl, C 6-20 Aryl,

[0186] Where R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R tIt is halogenated independently each time it appears.

[0187] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 1 It is a 5- to 9-membered heteroaryl group, optionally surrounded by one or more R groups. s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; wherein R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t Halogenation occurs independently each time it occurs. In some embodiments, R 1 It is a 5-membered heteroaryl group, optionally constituting one or more R groups. s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; wherein R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it occurs. In some such embodiments, R s It is C independently each time it appears. 1-2 Alkyl or C6 aryl; wherein R s The C6 aryl group is optionally enclosed by one or more R t Replace; where R t It is halogenated independently each time it occurs. In some such embodiments, R s C 1-2 alkyl, In some embodiments, R 1 for Optionally by one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; wherein R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it occurs. In some such embodiments, R s It is C independently each time it appears. 1-2 Alkyl or C6 aryl; wherein R s The C6 aryl group is optionally enclosed by one or more Rt Replace; where R t It is halogenated independently each time it occurs. In some such embodiments, R s C 1-2 alkyl, In some embodiments, R 1 It is a 9-membered heteroaryl group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; wherein R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it occurs. In some embodiments, R 1 It is a 9-membered heteroaryl group, optionally surrounded by one or more R s Replace, where R s It is either halogenated or amine-based each time it appears. In some embodiments, R 1 for Optionally by one or more R s Replace, where R s Each time it appears, it is independently either halogenated or amine-based.

[0188] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0189] L 2 -R 2 It is cyclopropyl;

[0190] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0191] R 1 It is a 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0192] Where Rs C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl,

[0193] Where R s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

[0194] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein R 1 It is a 4- to 10-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl, C 1-6 Alkyl; wherein R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl; and R in which s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

[0195] In some embodiments, R 1 It is a 4-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl, C 1-6 Alkyl; wherein R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl; and R in which s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R uIt is independently halogenated or C each time it appears. 1-6 Alkyl group. In some such embodiments, R 1 It is a 4-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently a hydroxyl group, a 5- to 20-membered heteroaryl group, or optionally surrounded by one or more R groups. t Replacement C 1-6 Alkyl; wherein R t It is C independently each time it appears. 6-20 Aryl. In some such embodiments, R s Each time it appears, it is independently hydroxyl, pyridine, or optionally accompanied by one or more R... t Substituted C1 alkyl; wherein R t It is independently C6 aryl each time it appears. In some embodiments, R 1 for Optionally by one or more R s Replace, where R s Each time it appears, it is independently a hydroxyl group, a 5- to 20-membered heteroaryl group, or optionally surrounded by one or more R groups. t Replacement C 1-6 Alkyl; wherein R t It is C independently each time it appears. 6-20 Aryl. In some such embodiments, R s Each time it appears, it is independently hydroxyl, pyridine, or optionally accompanied by one or more R... t Substituted C1 alkyl; wherein R t It is independently C6 aryl each time it appears.

[0196] In some embodiments, R 1 It is a 5-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl, C 1-6 Alkyl; wherein R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl; and R in which s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 Alkyl group. In some such embodiments, R 1It is a 5-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s C 6-20 Aryl, and in which R s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 Alkyl group. In some such embodiments, R s It is C6 aryl, optionally with one or more R u Replace; where R u It is independently C1 alkyl or chlorinated each time it appears. In some embodiments, R 1 for Optionally by one or more R s Replace, where R s C 6-20 Aryl, and in which R s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 Alkyl group. In some such embodiments, R s It is C6 aryl, optionally with one or more R u Replace; where R u Each time it appears, it is independently C1 alkyl or chlorinated.

[0197] In some embodiments, R 1 It is a 10-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl, C 1-6 Alkyl; wherein R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl; and R in which s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 Alkyl group. In some such embodiments, R 1 It is a 10-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R sEach time it appears, it is independently either oxidized or C. 6-20 Aryl. In some such embodiments, R s It is independently oxo or C6 aryl each time it appears. In some embodiments, R 1 A 10-membered heterocyclic group comprising one or more heteroatoms selected from the group consisting of O and S, optionally separated by one or more R s Replace, where R s Each time it appears, it is independently either oxidized or C. 6-20 Aryl. In some such embodiments, R s It is independently oxo or C6 aryl each time it appears. In some embodiments, R 1 for Optionally by one or more R s Replace, where R s Each time it appears, it is independently either oxidized or C. 6-20 Aryl. In some such embodiments, R s Each time it appears, it is independently oxo or C6 aryl.

[0198] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0199] L 1 -R 1 It is methyl;

[0200] L 2 For key or C 1-12 Alkyl; and

[0201] R 2 Choose from the following groups:

[0202] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein L 2 For the bond or -CH2-.

[0203] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0204] L 1 -R 1 It is methyl;

[0205] L 2 For a bond or -CH2-; and

[0206] R 2 Choose from the following groups:

[0207] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0208] L 1 -R 1 It is methyl;

[0209] L 2 As a key; and

[0210] R 2 Choose from the following groups:

[0211] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0212] L 1 -R 1 It is methyl;

[0213] L 2 It is -CH2-; and

[0214] R 2 Choose from the following groups:

[0215] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0216] L 2 -R 2 It is cyclopropyl;

[0217] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 Alkyl; and

[0218] R 1 Choose from the following groups:

[0219] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein L 1 Choose from the following groups of bonds: -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- and -CH(CH2CH3)CH2-.

[0220] In some embodiments, this document provides a compound of formula (I) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0221] L 2 -R 2 It is cyclopropyl;

[0222] L 1 Choose from the following groups of bonds: -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; and

[0223] R 1 Choose from the following groups:

[0224] In some embodiments, a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, is provided, wherein:

[0225] L 2 -R 2 It is cyclopropyl;

[0226] L 1 As a key; and

[0227] R 1 Choose from the following groups:

[0228] In some embodiments, a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, is provided, wherein:

[0229] L 2 -R 2 It is cyclopropyl;

[0230] L 1Choose the group consisting of the following: -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; and

[0231] R 1 Choose from the following groups:

[0232] In some embodiments, a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, is provided, wherein the compound is selected from the group consisting of:

[0233]

[0234] In some embodiments, a compound of formula (I) or a pharmaceutical salt thereof is provided, wherein the compound is selected from the group consisting of:

[0235] In another embodiment, a compound of formula (II) is provided:

[0236]

[0237] Or its stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, wherein:

[0238] I)L 1 -R 1 It is methyl;

[0239] L 2 For key or C 1-12 alkyl;

[0240] R 2 for

[0241] i)-OC 6-20 aryl, optionally constituting one or more R s Replace; where R s It is halogenated independently each time it appears;

[0242] ii) 4- to 20-membered heterocyclic groups, optionally surrounded by one or more R groups. s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0243] iii) Mixed aromatic compounds ranging from 5 to 20 yuan, of which R 2 The 5- to 20-yuan heteroaryl group is affected by one or more R s Replace; where R s It is independently halogenated or C each time it appears. 1-12 alkyl;

[0244] iv)C 6-20 cycloalkyl, optionally with one or more R s Replace; where R s It is independently -C(O)OC each time it appears. 1-6 alkyl;

[0245] v)-N(CH3)-C 6-20 Aryl;

[0246] iv)-C 6-20 aryl, optionally constituting one or more R s Replace; where R s It is C independently each time it appears. 1-6 Halogenated alkyl; or

[0247] II)L 2 -R 2 It is cyclopropyl;

[0248] L 1 For key or C 1-12 Alkyl; wherein L 1 C 1-12 Alkyl groups are optionally surrounded by one or more R e Replace; where R e It is C independently each time it appears. 1-6 Alkyl or hydroxy C 1-6 alkyl;

[0249] R 1 for

[0250] i)-L 3 -C 6-20 Aryl; of which L 3 For O or C(O)NH; -L 3 -C 6-20 C of aryl 6-20 Aryl group is optionally bounded by one or more R s Replace, where R s It is independently a halogenated C each time it appears. 1-6 alkyl;

[0251] ii)C 4-20 cycloalkyl, optionally with one or more R s Replace; where R sEach time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl;

[0252] iii)C 6-20 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl;

[0253] Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5 to 20 yuan heteroaryl group is optionally occupied by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl;

[0254] iv) 5 to 20 yuan of heteroaryl groups, optionally coated with one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl;

[0255] Where R s C 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears; or

[0256] v) A 4- to 20-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl;

[0257] Where R s C 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl,

[0258] Where R s C 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 alkyl.

[0259] It should be understood that any method of preparing or using compounds of formula (I) also applies to compounds of formula (II).

[0260] In some embodiments, this document provides a compound of formula (II) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0261] L 1 -R 1 It is methyl;

[0262] L 2 For key or C 1-12 Alkyl; and

[0263] R 2 Choose from the following groups:

[0264]

[0265] In some embodiments, this document provides a compound of formula (II) or any applicable subform thereof, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the foregoing, wherein:

[0266] L 2 -R 2 It is cyclopropyl;

[0267] L 1 Choose from the following groups of bonds: -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2-, and -CH(CH2CH3)CH2-; and

[0268] R 1 Choose from the following groups:

[0269]

[0270] The compounds described herein include those listed in Tables 1-A, 1-B, or 1-C, or their stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing.

[0271] Table 1-A

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287]

[0288]

[0289]

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492]

[0493]

[0494]

[0495]

[0496]

[0497]

[0498]

[0499]

[0500]

[0501]

[0502]

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

[0521]

[0522]

[0523]

[0524]

[0525]

[0526]

[0527]

[0528]

[0529]

[0530]

[0531]

[0532]

[0533]

[0534]

[0535]

[0536]

[0537]

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544]

[0545]

[0546]

[0547]

[0548]

[0549]

[0550]

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561]

[0562]

[0563]

[0564]

[0565]

[0566]

[0567]

[0568]

[0569]

[0570]

[0571]

[0572]

[0573]

[0574]

[0575]

[0576]

[0577]

[0578]

[0579]

[0580]

[0581]

[0582]

[0583]

[0584]

[0585]

[0586]

[0587]

[0588]

[0589] Table 1-B

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597]

[0598]

[0599]

[0600]

[0601]

[0602]

[0603]

[0604]

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612]

[0613]

[0614]

[0615]

[0616]

[0617]

[0618]

[0619]

[0620]

[0621]

[0622]

[0623]

[0624]

[0625]

[0626]

[0627]

[0628]

[0629]

[0630]

[0631]

[0632]

[0633]

[0634]

[0635]

[0636]

[0637]

[0638]

[0639]

[0640]

[0641]

[0642]

[0643]

[0644]

[0645]

[0646]

[0647]

[0648]

[0649]

[0650]

[0651]

[0652]

[0653]

[0654]

[0655]

[0656]

[0657]

[0658]

[0659]

[0660]

[0661]

[0662]

[0663]

[0664]

[0665]

[0666]

[0667]

[0668]

[0669]

[0670]

[0671]

[0672]

[0673]

[0674]

[0675]

[0676]

[0677]

[0678]

[0679]

[0680]

[0681]

[0682]

[0683]

[0684]

[0685]

[0686]

[0687]

[0688]

[0689]

[0690]

[0691]

[0692]

[0693]

[0694]

[0695]

[0696]

[0697]

[0698]

[0699]

[0700]

[0701]

[0702]

[0703]

[0704]

[0705]

[0706]

[0707]

[0708]

[0709]

[0710]

[0711]

[0712]

[0713]

[0714]

[0715]

[0716]

[0717]

[0718]

[0719]

[0720]

[0721]

[0722]

[0723]

[0724]

[0725]

[0726]

[0727]

[0728]

[0729]

[0730]

[0731]

[0732]

[0733]

[0734]

[0735]

[0736]

[0737]

[0738]

[0739]

[0740] Table 1-C

[0741]

[0742]

[0743]

[0744]

[0745]

[0746]

[0747]

[0748]

[0749]

[0750]

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759]

[0760]

[0761]

[0762]

[0763]

[0764]

[0765]

[0766]

[0767]

[0768]

[0769]

[0770]

[0771]

[0772]

[0773]

[0774]

[0775]

[0776]

[0777]

[0778]

[0779]

[0780]

[0781]

[0782]

[0783]

[0784]

[0785]

[0786]

[0787]

[0788]

[0789]

[0790]

[0791]

[0792]

[0793]

[0794]

[0795]

[0796]

[0797]

[0798]

[0799]

[0800]

[0801]

[0802]

[0803]

[0804]

[0805]

[0806]

[0807] In some embodiments, compounds of Table 1-A, Table 1-B, or Table 1-C are provided herein. In some embodiments, stereoisomers or tautomers of compounds of Table 1-A, Table 1-B, or Table 1-C are provided herein. In some embodiments, pharmaceutical salts of compounds of Table 1-A, Table 1-B, or Table 1-C, or stereoisomers or tautomers thereof, are provided herein.

[0808] In one embodiment, the present invention provides a compound selected from the group consisting of:

[0809] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-1-(4-methylpyrimidin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[0810] (2S,4R)-N-[2-(4-bromo-N-methylaniline)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[0811] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-phenylpiperazin-1-yl)sulfonylpropyl]pyrrolidine-2-carboxamide;

[0812] (2S,4R)-N-[(2-cyclopropyl-2-azabicyclo[2.1.1]hex-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0813] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(2R,5R)-5-phenyltetrahydrofuran-2-yl]methyl]pyrrolidine-2-carboxamide;

[0814] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-1-(3-methylimidazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[0815] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-oxo-3,4-dihydro-1H-quinolin-4-yl)methyl]pyrrolidine-2-carboxamide;

[0816] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6,6-difluoro-3-bicyclo[3.1.0]hexyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0817] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methyl-3-methylsulfonyl-phenyl)methyl]pyrrolidine-2-carboxamide;

[0818] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0819] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1,2,2-trimethylpyrrolidin-3-yl)pyrrolidin-2-carboxamide;

[0820] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrrolidine-2-carboxamide;

[0821] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3,6-dihydro-2H-pyridin-1-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0822] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-(4-fluorophenyl)tetrazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0823] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[4-(2-pyridyl)triazol-2-yl]ethyl]pyrrolidine-2-carboxamide;

[0824] (2S,4R)-N-[(3aS,6R,6aR)-1-benzyl-3,3a,4,5,6,6a-hexahydro-2H-cyclopentadieno[b]pyrrolo-6-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0825] (2S,4R)-N-[(5-Cyclopropylisoxazol-4-yl)methyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0826] (2S,4R)-N-[2-(4-chlorophenyl)-3-(dimethylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[0827] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-pyrrolidone-1-ylcyclohexyl)methyl]pyrrolidone-2-carboxamide;

[0828] 6-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-3,4-dihydro-1H-pyrrolo[2,1-c][1,4]oxazine-8-carboxamide;

[0829] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(3,3,3-trifluoropropoxy)-4-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[0830] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-methyl-4-oxo-phthalazin-1-yl)methyl]pyrrolidine-2-carboxamide;

[0831] (2S,4R)-N-(8-chloro-2,3,4,5-tetrahydro-1-benzoxazine) -5-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0832] (2S,4R)-N-[[1-(cyclopropylmethyl)tetrazol-5-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0833] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydroquinazolin-6-yl)pyrrolidine-2-carboxamide;

[0834] (2S,4R)-N-[2-(2-chloro-4-fluoro-phenyl)-3,3,3-trifluoro-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0835] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-(4-fluorophenyl)thiazolyl-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0836] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(1-phenyltetrazole-5-yl)amino]ethyl]pyrrolidine-2-carboxamide;

[0837] (2S,4R)-N-[[1-(2-chlorophenyl)triazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0838] (2S,4R)-N-[cyclohexyl(3-pyridinyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0839] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-(1-phenylpyrazole-4-yl)cyclopropyl]pyrrolidine-2-carboxamide;

[0840] (2S,4R)-N-(3-cyclopropyl-3-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0841] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,3S)-2,2-dimethyl-3-phenoxy-cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0842] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(6-methyl-1,1-dioxo-thiazide-3-yl)pyrrolidine-2-carboxamide;

[0843] (2S,4R)-N-[(1R,2R,4S)-4-cyano-2-hydroxy-cyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0844] (2S,4R)-N-[[3-(4-cyanophenyl)-1-methyl-pyrazole-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0845] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-ethyl-3-oxo-4H-1,4-benzoxazin-7-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0846] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-methyl-4-(3-oxopiperazin-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide;

[0847] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-isopropyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide;

[0848] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-[(2-ethylthiazolyl-4-yl)methyl]-4-piperidinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0849] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(2-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-6-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0850] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[5-[(4-fluorophenoxy)methyl]-1,2,4-oxadiazol-3-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0851] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-(1-naphthyl)cyclopropyl]pyrrolidine-2-carboxamide;

[0852] (2S,4R)-N-[2-cyclopropyl-1-(3-fluoro-4-methyl-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0853] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-hydroxy-2-methyl-propyl)azacyclobutane-3-yl]pyrrolidine-2-carboxamide;

[0854] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2R)-2-(difluoromethyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0855] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(5,5-dimethyl-2-oxo-pyrrolidine-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0856] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-2-(4-phenylphenyl)ethyl]pyrrolidine-2-carboxamide;

[0857] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[5-(difluoromethyl)isoxazol-3-yl]-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0858] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,4-dimethoxyphenyl)-(4-methoxyphenyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0859] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(1-methyl-4-piperidinyl)amino]-2-oxo-ethyl]pyrrolidine-2-carboxamide;

[0860] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[2-fluoro-6-(methanesulfonylamino)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0861] (2S,4R)-N-[cyclopropyl(tetrahydropyran-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0862] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methyl-5-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide;

[0863] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3-fluoro-4-methyl-2-pyridinyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0864] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-oxabicyclo[4.1.0]heptane-7-yl)pyrrolidine-2-carboxamide;

[0865] (2S,4R)-N-[(6-amino-2,4-dimethyl-3-pyridinyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0866] (2S,4R)-N-[1-[1-[1-(4-bromopyrazol-1-yl)cyclopropyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0867] (2S,4R)-N-[1-Cyclopropyl-2-(1,1-dioxo-1,2-thiazolidin-2-yl)ethyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0868] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[5-(methoxymethyl)oxazol-4-yl]methyl]pyrrolidine-2-carboxamide;

[0869] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1'R,4R)-spiro[chroman-4,2'-cyclopropane]-1'-yl]pyrrolidine-2-carboxamide;

[0870] (2S,4R)-N-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0871] (2S,4R)-N-[2-[(4-chloro-2-fluoro-phenyl)sulfonylamino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0872] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[(2-fluorophenyl)methyl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0873] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[2-(2,2-dimethylpropionylamino)thiazolyl-4-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0874] (2S,4R)-N-(2-cyclopentyl-4,5,6,7-tetrahydroindazole-7-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0875] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-methyl-2-(4-pyridyl)propyl]pyrrolidine-2-carboxamide;

[0876] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2-fluorophenyl)sulfinylethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0877] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-(difluoromethyl)-2-methyl-pyrazol-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0878] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3-methoxyphenyl)-2-methyl-propyl]pyrrolidine-2-carboxamide;

[0879] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-methylpyrimidin-2-yl)methyl]pyrrolidine-2-carboxamide;

[0880] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(tetrazol-2-yl)ethyl]pyrrolidine-2-carboxamide;

[0881] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-isooxazol-4-ylpropyl)pyrrolidine-2-carboxamide;

[0882] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-hydroxy-5,6-dimethyl-pyridazin-4-yl)methyl]pyrrolidine-2-carboxamide;

[0883] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(5-fluoro-1-methyl-benzimidazol-2-yl)propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0884] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-isopropyl-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-7-yl)pyrrolidine-2-carboxamide;

[0885] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4,4-dioxo-2,3-dihydro-1,4λ6-benzoxythiacyclohexadien-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0886] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,1-dioxothiazane-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0887] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-methyl-6-oxo-3-piperidinyl)methyl]pyrrolidine-2-carboxamide;

[0888] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4-pyridyl)cyclopropyl]pyrrolidine-2-carboxamide;

[0889] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyl-2,3-dihydrobenzofuran-3-yl)pyrrolidine-2-carboxamide;

[0890] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-(1-ethylpropyl)isoxazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0891] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-methoxy-1-piperidinyl)ethyl]pyrrolidine-2-carboxamide;

[0892] (2S,4R)-N-(1-benzyl-2-thiazolyl-4-yl-ethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0893] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(1-methylimidazol-4-yl)-2-pyrrolidine-1-yl-ethyl]pyrrolidine-2-carboxamide;

[0894] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(6-methoxy-2-pyridinyl)ethyl]pyrrolidine-2-carboxamide;

[0895] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-thiazolyl-2-ylcyclopentyl)pyrrolidine-2-carboxamide;

[0896] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-[(4-methyl-1-piperidinyl)sulfonylmethyl]phenyl]methyl]pyrrolidine-2-carboxamide;

[0897] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-2-(2,5-dimethoxy-4-methyl-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0898] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-methyl-6-oxo-pyrimidin-1-yl)ethyl]pyrrolidine-2-carboxamide;

[0899] (2S,4R)-N-[2-(5-amino-1,3,4-oxadiazol-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0900] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[6-(1,1-difluoroethyl)-2-pyridinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0901] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-2-pyrazin-2-yl-ethyl)pyrrolidine-2-carboxamide;

[0902] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(dimethylamino)-2-(4-ethylphenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0903] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)methyl]pyrrolidine-2-carboxamide;

[0904] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4,4-difluoro-1-methyl-3-piperidinyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0905] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2,2-dimethyl-1-pyrimidin-2-yl-propyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0906] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3-hydroxyphenyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide;

[0907] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-1-[2-(trifluoromethoxy)phenyl]ethyl]pyrrolidine-2-carboxamide;

[0908] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,2-difluorocyclopropoxy)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0909] (2S,4R)-N-[2-(4-bromotriazol-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0910] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0911] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(imidazol-1-ylmethyl)phenyl]methyl]pyrrolidine-2-carboxamide;

[0912] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[6-(2-methylmorpholin-4-yl)-3-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[0913] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-methyl-1-piperidinyl)-2-phenyl-ethyl]pyrrolidine-2-carboxamide;

[0914] (2S,4R)-N-[4-(1,3-benzoxazol-2-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0915] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3-oxomorpholin-4-yl)ethyl]pyrrolidine-2-carboxamide;

[0916] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(4-methoxyphenyl)pyrazole-3-yl]methyl]pyrrolidine-2-carboxamide;

[0917] (2S,4R)-N-[[6-(cyclohexyloxy)-3-pyridinyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0918] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(7-oxo-6-azabicyclo[3.2.1]octane-5-yl)methyl]pyrrolidine-2-carboxamide;

[0919] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[5-(3-fluorophenyl)-1,3,4-thiadiazol-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0920] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[2-(m-tolyl)cyclopropyl]ethyl]pyrrolidine-2-carboxamide;

[0921] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[5-oxo-1-(4-phenoxyphenyl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[0922] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-fluoro-3-[(3-methoxyphenoxy)methyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0923] (2S,4R)-N-[[4-(3-chlorophenoxy)-2-pyridinyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0924] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-(4-ethoxyphenyl)tetrahydropyran-4-yl]methyl]-4-hydroxypyrrolidine-2-carboxamide;

[0925] (2S,4R)-N-(2-benzylsulfinylethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0926] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3,3,3-trifluoro-2-hydroxy-2-(1-methylimidazol-2-yl)propyl]pyrrolidine-2-carboxamide;

[0927] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(1R,2R,4S)-2-hydroxy-4-(4-methyl-1,2,4-triazol-3-yl)cyclopentyl]methyl]pyrrolidine-2-carboxamide;

[0928] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[4-hydroxy-2-[4-(trifluoromethyl)phenyl]butyl]pyrrolidine-2-carboxamide;

[0929] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide;

[0930] (2S,4R)-N-[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]thio]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0931] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[2-(difluoromethoxy)-4-propoxy-phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0932] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-(thiazolyl-2-ylamino)ethyl]pyrrolidine-2-carboxamide;

[0933] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(4-cyclopropyltriazol-1-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0934] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-hydroxy-1-methyl-pyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide;

[0935] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[5-(1-piperidinylsulfonyl)-2-thienyl]methyl]pyrrolidine-2-carboxamide;

[0936] (2S,4R)-N-[2-(3-benzyloxyphenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0937] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-[[4-(trifluoromethyl)phenyl]methyl]tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide;

[0938] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(methylsulfonylmethyl)oxetane-3-yl]pyrrolidine-2-carboxamide;

[0939] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[2-(1,1-dioxo-1,2-thiazolidin-2-yl)cyclopentyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0940] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-phenylisothiazo-5-yl)methyl]pyrrolidine-2-carboxamide;

[0941] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-fluoro-1-(2-methylpropionyl)azacyclobutane-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0942] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-3-(1-naphthyloxy)propyl]pyrrolidine-2-carboxamide;

[0943] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(4-methylpiperazin-1-yl)pyrimidin-4-yl]methyl]pyrrolidine-2-carboxamide;

[0944] (2S,4R)-N-[(5-cyano-3-pyridinyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0945] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[phenyl(thiazo-2-yl)methyl]pyrrolidine-2-carboxamide;

[0946] (2S,4R)-N-(1-carbamoyl-1-cyclopropyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0947] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(4-methyl-3-oxo-piperazin-1-yl)pyrazin-2-yl]methyl]pyrrolidine-2-carboxamide;

[0948] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-phenylthiazo-2-yl)methyl]pyrrolidine-2-carboxamide;

[0949] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-oxo-4H-1,4-benzoxazin-5-yl)methyl]pyrrolidine-2-carboxamide;

[0950] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-methylpyrazolo[1,5-a]pyrazin-4-yl)azacyclobutane-3-yl]pyrrolidine-2-carboxamide;

[0951] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-oxopyrimidin-1-yl)ethyl]pyrrolidine-2-carboxamide;

[0952] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(5-methyl-1,3,4-oxadiazol-2-yl)cyclobutyl]pyrrolidine-2-carboxamide;

[0953] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[5-(3-pyridinyl)-3-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[0954] (2S,4R)-N-[[6-(benzimidazol-1-yl)-3-pyridyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0955] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[6-(4-fluorophenoxy)-2-pyridinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0956] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-1-[4-(trifluoromethyl)phenyl]pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[0957] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-(4-isopropylphenyl)cyclopropyl]pyrrolidine-2-carboxamide;

[0958] (2S,4R)-N-[(3-amino-1,2-benzoxazol-6-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0959] (2S,4R)-N-(3,4,6,7,8,8a-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0960] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6,7-dihydro-4H-pyrano[4,3-d]thiazolyl-2-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0961] (2S,4R)-N-[(1-carbamoylcyclopropyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0962] (2S,4R)-N-[(4-cyclopropyl-3-fluoro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0963] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(4-quinolinyl)propyl]pyrrolidine-2-carboxamide;

[0964] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-methyldiazacycloheptane-3-yl)methyl]pyrrolidine-2-carboxamide;

[0965] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide;

[0966] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-pyrazol-1-ylphenyl)ethyl]pyrrolidine-2-carboxamide;

[0967] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,3-dimethylimidazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0968] (2S,4R)-N-[(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-phenyl-methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0969] (2S,4R)-N-[[5-(tert-butoxymethyl)isoxazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0970] (2S,4R)-N-[(2-Cyclopropylthiazolyl-4-yl)methyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0971] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4,5-dimethyloxazol-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0972] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethoxy)cyclohexyl]methyl]pyrrolidine-2-carboxamide;

[0973] (2S,4R)-N-[(5-cyclopropyl-1,3,4-oxadiazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0974] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyl-2-oxo-1-phenyl-pyrrolidine-3-yl)pyrrolidine-2-carboxamide;

[0975] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R)-2-(6-methoxy-2-naphthyl)-1-methyl-ethyl]pyrrolidine-2-carboxamide;

[0976] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(imidazo[1,2-a]pyridin-7-ylmethyl)pyrrolidine-2-carboxamide;

[0977] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(4,6-dichloroindan-1-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0978] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(8-fluorothiochroman-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[0979] (2S,4R)-N-[[1-(tert-butylaminosulfonyl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0980] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(2-methyltriazol-4-yl)propyl]pyrrolidine-2-carboxamide;

[0981] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-morpholinosulfonylphenyl)methyl]pyrrolidine-2-carboxamide;

[0982] (2S,4R)-N-[1-(4-bromo-3-fluoro-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0983] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(5-methyl-1,3,4-thiadiazol-2-yl)propyl]pyrrolidine-2-carboxamide;

[0984] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(2-oxo-1-piperidinyl)-1-bicyclo[1.1.1]pentyl]pyrrolidine-2-carboxamide;

[0985] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-oxo-2-phenyl-pyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide;

[0986] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-methylcyclopropyl)-5-oxo-pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[0987] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[1-(4-fluorophenyl)-1-methyl-ethyl]cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0988] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(4-methylsulfonylphenyl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide;

[0989] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0990] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-isobutyl-5-methyl-pyrazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[0991] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[[2-(trifluoromethyl)benzoyl]amino]ethyl]pyrrolidine-2-carboxamide;

[0992] (2S,4R)-N-[(1R,2S)-2-(4-bromopyrazol-1-yl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[0993] (2S,4R)-N-[(6-bromo-1,3-benzoxazol-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0994] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2,6-dichlorophenyl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0995] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[2,2-difluoroethyl(ethyl)amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0996] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(7-methyl-6-oxaspiro[3.4]octane-2-yl)pyrrolidine-2-carboxamide;

[0997] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-isopropoxycyclobutyl)pyrrolidine-2-carboxamide;

[0998] (2S,4R)-N-[(3R,5R)-5-tert-butyl-2-oxo-pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[0999] (2S,4R)-N-(2-acetyl-1,3,3a,4,5,6,7,7a-octahydroisoindole-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1000] (2S,4R)-N-[(2-cyclohexylpyrazole-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1001] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[5-(1-piperidinyl)-1,3,4-oxadiazol-2-yl]methyl]pyrrolidine-2-carboxamide;

[1002] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3-fluorophenyl)-(2-pyridyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1003] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,5-diazabicyclo[3.2.2]nonane-6-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1004] (2S,4R)-N-[(3S,4R)-1-benzyl-4-(3-fluorophenyl)pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1005] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[(3,5-dimethoxyphenyl)methyl]pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1006] (2S,4R)-N-[(6-chloro-8-methyl-imidazo[1,2-a]pyridin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1007] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-[2-(dimethylamino)ethyl]-4-piperidinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1008] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-oxopyrazolo[1,5-a]pyrazin-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1009] (2S,4R)-N-(4-cyclopropyl-2-hydroxy-butyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1010] (2S,4R)-N-[(1-benzyl-2-methyl-pyrrolidone-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidone-2-carboxamide;

[1011] (2S,4R)-N-[3-amino-2-[(2-chlorophenyl)methyl]-3-oxopropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1012] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-(3-quinolinylamino)ethyl]pyrrolidine-2-carboxamide;

[1013] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(isoxazo-3-ylmethylsulfonylamino)ethyl]pyrrolidine-2-carboxamide;

[1014] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2R,3R)-2-(trifluoromethyl)chroman-3-yl]pyrrolidine-2-carboxamide;

[1015] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(1-oxophthalazin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1016] (2S,4R)-N-[3-(3-cyanophenyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1017] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1,1-dioxo-2-phenyl-1,2-thiazolidin-5-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1018] (2S,4R)-N-[(3-cyclopropyl-4,5-dihydroisoxazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1019] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[(2-phenyloxazol-4-yl)methyl]-4-piperidinyl]pyrrolidine-2-carboxamide;

[1020] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[6-[2-(trifluoromethyl)phenoxy]-3-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[1021] (2S,4R)-N-(2-Cyclopropyl-2-hydroxy-2-phenyl-ethyl)-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1022] (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(phenoxymethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1023] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(3-phenylpropyl)imidazol-2-yl]methyl]pyrrolidine-2-carboxamide;

[1024] (2S,4R)-N-[6-bromo-2-(hydroxymethyl)tetrahydronaphthyl-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[1025] 2-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-1-piperidinyl]pyridine-3-carboxamide;

[1026] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[6-fluoro-2-(4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1027] (2S,4R)-N-[[1-[(5-tert-butyl-1,2,4-oxadiazol-3-yl)methyl]-3-piperidinyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1028] (2S,4R)-N-[(3-cyano-2-fluoro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1029] 3-[1-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]-1-methyl-ethyl]-1,2,4-oxadiazole-5-carboxamide;

[1030] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[4-(difluoromethyl)-6-methyl-pyrimidin-2-yl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1031] (2S,4R)-N-[(1-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1032] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-2,2-dioxo-3,4-dihydro-2λ6,1-benzothiazin-4-yl)pyrrolidine-2-carboxamide;

[1033] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methyl-2-phenyl-triazol-5-yl)methyl]pyrrolidine-2-carboxamide;

[1034] (2S,4R)-N-[[3-(cyclopropylsulfonylamino)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1035] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-isopropylisooxazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[1036] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[3-[[2-(2-fluorophenyl)acetyl]amino]phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1037] (2S,4R)-N-[2-(4-chlorophenyl)-3,3,3-trifluoro-2-hydroxypropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[1038] (2S,4R)-N-[1-(4-cyano-2-fluoro-phenyl)-3-piperidinyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1039] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-hydroxy-5,6,7,8-tetrahydroquinoline-3-yl)methyl]pyrrolidine-2-carboxamide;

[1040] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(6-morpholinopyrimidin-4-yl)-3-piperidinyl]pyrrolidine-2-carboxamide;

[1041] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(triazol-1-ylmethyl)cyclobutyl]pyrrolidine-2-carboxamide;

[1042] (2S,4R)-N-[2-[(1-cyanocyclopropyl)methylamino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1043] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[4-(3-fluorophenyl)-4-hydroxy-cyclohexyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1044] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(1-methyl-5-oxo-pyrrolidine-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1045] (2S,4R)-N-(chroman-6-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1046] (2S,4R)-N-[(4-cyclopropyl-2-methyl-pyrazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1047] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R)-1-(5-isoquinolinyl)ethyl]pyrrolidine-2-carboxamide;

[1048] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methylthiadiazol-5-yl)methyl]pyrrolidine-2-carboxamide;

[1049] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2,2-dimethyl-3-pyrrolidone-1-yl-propyl)-4-hydroxy-pyrrolidone-2-carboxamide;

[1050] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-methylcyclopropyl)-phenyl-methyl]pyrrolidine-2-carboxamide;

[1051] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(1-oxo-2-isoquinolinyl)propyl]pyrrolidine-2-carboxamide;

[1052] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[3-(methylcarbamoyl)phenyl]ethyl]pyrrolidine-2-carboxamide;

[1053] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2,4-difluorophenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1054] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(5-isopropyl-2-methyl-1,2,4-triazol-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1055] (2S,4R)-N-[2-(2-amino-4-pyridinyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1056] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3,3,4-trimethylpiperazin-1-yl)ethyl]pyrrolidine-2-carboxamide;

[1057] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(4-methylthiazolyl-5-yl)propyl]pyrrolidine-2-carboxamide;

[1058] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(6-methyl-2-pyrrolidone-1-yl-3-pyridinyl)methyl]pyrrolidone-2-carboxamide;

[1059] (2S,4R)-N-[2-(4-bromophenyl)sulfonyl-2-methyl-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1060] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(7-oxozyne-4-yl)pyrrolidine-2-carboxamide;

[1061] (2S,4R)-N-(5-cyanoindan-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1062] (2S,4R)-N-[[(2R,3S)-1-cyclopropyl-5-oxo-2-(4-pyridyl)pyrrolidine-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1063] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(oxazol-4-ylmethyl)pyrrolidine-2-carboxamide;

[1064] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-[4-(2-pyridyl)piperazin-1-yl]ethyl]pyrrolidine-2-carboxamide;

[1065] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(4-fluoro-1-naphthyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1066] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methyl-2-pyridinyl)-tetrahydropyran-4-yl-methyl]pyrrolidine-2-carboxamide;

[1067] (2S,4R)-N-[2-(3-benzyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1068] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-(difluoromethyl)-1-methyl-triazol-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1069] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-[(3-hydroxypyrrolidin-1-yl)methyl]phenyl]methyl]pyrrolidin-2-carboxamide;

[1070] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-fluoro-5-methyl-phenyl)-2-oxo-3-piperidinyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1071] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-[2-(dimethylamino)ethyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1072] (2S,4R)-N-(1-cyclohexyl-2-oxo-3-piperidinyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1073] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(4-phenylthiazo-2-yl)tetrahydropyran-4-yl]methyl]pyrrolidine-2-carboxamide;

[1074] (2S,4R)-N-(5'-bromospiro[cyclopropane-2,1'-indan]-1-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1075] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3-fluoro-2-pyridinyl)-2-methyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1076] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-ethyl]pyrrolidine-2-carboxamide;

[1077] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]ethyl]pyrrolidine-2-carboxamide;

[1078] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6-fluoro-1,1-dioxo-3,4-dihydro-2H-thiochromene-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1079] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-hydroxytetrahydropyran-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide;

[1080] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-1-(2-isopropylthiazolyl-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1081] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(4,5-dimethylthiazo-2-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1082] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[7-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl]pyrrolidine-2-carboxamide; (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1083] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-(5-quinolinylamino)ethyl]pyrrolidine-2-carboxamide;

[1084] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-[1-(2-pyridinyl)ethylamino]ethyl]pyrrolidine-2-carboxamide;

[1085] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(3-oxo-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-2-yl)propyl]pyrrolidine-2-carboxamide;

[1086] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R)-1-methyl-2-(1-methyltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1087] (2S,4R)-N-[2-cyclopentyl-2-(dimethylaminosulfonylamino)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1088] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,2-dimethyl-1,1-dioxo-thiapentane-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1089] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(pyridin-2-carbonyl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1090] (2S,4R)-N-[[2-bromo-5-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1091] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[3-(dimethylaminosulfonyl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1092] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl]pyrrolidine-2-carboxamide;

[1093] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,2-dimethyl-3-piperidinyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1094] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-methyl-2-(2-methylpyrazol-3-yl)butyl]pyrrolidine-2-carboxamide;

[1095] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(4-methylthiazolyl-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide;

[1096] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2,2-difluoronorcare-7-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1097] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3,5-dimethyl-1-(o-tolyl)pyrazol-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1098] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-2-oxo-5,6,7,8-tetrahydroquinoline-5-yl)pyrrolidine-2-carboxamide;

[1099] (2S,4R)-N-[[2-chloro-6-[methyl(3-pyridylmethyl)amino]phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1100] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-hydroxy-3-(trifluoromethyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide;

[1101] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-([1,2,4]triazolo[4,3-b]pyridine-6-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1102] (2S,4R)-N-[3-[(1-benzyl-4-piperidinyl)oxy]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1103] (2S,4R)-N-[2-amino-1-(3-bromophenyl)-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1104] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-[2-(trifluoromethoxy)phenyl]cyclopropyl]pyrrolidine-2-carboxamide;

[1105] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-[4-(1,2,4-triazol-1-yl)anilino]ethyl]pyrrolidine-2-carboxamide;

[1106] (2S,4R)-N-[(6R,7R)-2-benzyl-6-hydroxy-3-isopropyl-2-azaspiro[3.4]octane-7-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1107] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-ethylsulfonylphenyl)-4-piperidinyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1108] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-2-(2,4-difluorophenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1109] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[(1R,2R)-2-(2,6-difluorophenyl)cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1110] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[5-(diethylaminosulfonyl)-2-thienyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1111] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-oxo-3,4-dihydro-1H-1,8-naphthid-3-yl)pyrrolidine-2-carboxamide;

[1112] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[(2S,3R)-2-(1,5-dimethylpyrazole-4-yl)-1-methyl-5-oxo-pyrrolidine-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1113] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1114] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2R,3R,4S)-3-(trifluoromethyl)-7-oxabicyclo[2.2.1]heptane-2-yl]pyrrolidine-2-carboxamide;

[1115] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(2-hydroxyethoxy)-1,1-dioxo-thiapentane-3-yl]methyl]pyrrolidine-2-carboxamide;

[1116] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-[4-(1,2,4-triazol-1-ylmethyl)phenyl]phenyl]methyl]pyrrolidine-2-carboxamide;

[1117] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[6-(3,4-dihydro-2H-quinolin-1-yl)-3-pyridinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1118] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-[(3,4-dimethylphenyl)carbamoyl]cyclopentyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1119] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-methylimidazo[4,5-b]pyridin-2-yl)methyl]pyrrolidine-2-carboxamide;

[1120] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-pyrrolidone-1-yl-2-pyridinyl)methyl]pyrrolidone-2-carboxamide;

[1121] (2S,4R)-N-[2-(2-amino-4-methyl-thiazolyl-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1122] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1123] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-1-(4-methylsulfonylphenyl)ethyl]pyrrolidine-2-carboxamide;

[1124] (2S,4R)-N-[3-(cyclopropylsulfonylamino)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1125] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,4-dimethylphenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1126] (2S,4R)-N-[[(2S,4R)-1-benzyl-4-methoxy-pyrrolidine-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1127] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(4,6-difluoro-2,3-dihydrobenzofuran-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1128] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-pyrimidin-2-ylethyl)pyrrolidine-2-carboxamide;

[1129] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-ethyl-1,2,4-triazol-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1130] (2S,4R)-N-[2-[(2-chloro-6-fluoro-phenyl)methyl]-3-hydroxy-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1131] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[5-(difluoromethyl)-2-pyridinyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1132] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(1-methyltetrazole-5-yl)propyl]pyrrolidine-2-carboxamide;

[1133] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-3,4-dihydro-1H-isoquinoline-4-yl)pyrrolidine-2-carboxamide;

[1134] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-isooxazol-5-ylethyl)pyrrolidine-2-carboxamide;

[1135] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]methyl]pyrrolidine-2-carboxamide;

[1136] (2S,4R)-N-[cyclopropyl-(4-methylthiazolyl-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1137] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-pyrrolo-1-ylpropyl)pyrrolidin-2-carboxamide;

[1138] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(5-ethyl-2-oxo-dihydroindole-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1139] (2S,4R)-N-(8-cyclopropyl-8-azabicyclo[3.2.1]octane-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1140] N-(4-bromophenyl)-4-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]piperidine-1-carboxamide;

[1141] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,5-dichlorophenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1142] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[4-(difluoromethyl)pyrimidin-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1143] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3S,4R)-1-[2-(dimethylamino)pyrimidin-4-yl]-4-methoxy-pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1144] (2S,4R)-N-[(2-chloro-6-imidazol-1-yl-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1145] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-phenyl-2-(trifluoromethyl)cyclopropyl]pyrrolidine-2-carboxamide;

[1146] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)sulfonyl-4-piperidinyl]pyrrolidine-2-carboxamide;

[1147] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1,2,4-oxadiazol-3-yl)cyclopropyl]pyrrolidine-2-carboxamide;

[1148] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-(dimethylcarbamoyl)tetrahydrofuran-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1149] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3,4-difluorophenyl)-2-methyl-cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1150] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2S,4R)-2-phenylchroman-4-yl]pyrrolidine-2-carboxamide;

[1151] (2S,4R)-N-[(1S)-1-(3-bromoisooxazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1152] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[2-[2-(dimethylamino)-3-pyridinyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1153] (2S,4R)-N-[3-(4-acetylpiperazin-1-yl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1154] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2-fluorophenyl)-(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1155] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-hydroxychroman-3-yl)pyrrolidine-2-carboxamide;

[1156] (2S,4R)-N-[1-(5-cyano-2-pyridinyl)-4-piperidinyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1157] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[4,4,4-trifluoro-3-hydroxy-3-(5-methyloxazol-2-yl)butyl]pyrrolidine-2-carboxamide;

[1158] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-[(3-fluorophenyl)methylaminosulfonyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1159] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1160] (2S,4R)-N-[(1R,3S)-3-(cyanomethyl)cyclopentyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1161] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-(2,3-dihydrobenzofuran-5-yl)-4,5-dihydroisoxazo-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1162] (2S,4R)-N-[[(2S,3R)-1-cyclopropyl-2-(3-methylimidazol-4-yl)-3-piperidinyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1163] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1164] (2S,4R)-N-[(2-amino-3-methyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1165] (2S,4R)-N-[[1-(1,3-benzodioxacyclopenten-5-yl)cyclopropyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1166] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3R)-1-(3-methylisoxazol-5-carbonyl)-3-piperidinyl]pyrrolidine-2-carboxamide;

[1167] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3R)-1-(dimethylaminosulfonyl)-3-piperidinyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1168] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-tetrahydropyran-4-ylcyclopropyl)methyl]pyrrolidine-2-carboxamide;

[1169] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(1-methyltriazol-4-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide;

[1170] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(3-methylmorpholin-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1171] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-aminosulfonylpropyl)pyrrolidine-2-carboxamide;

[1172] (2S,4R)-N-[2-(4-cyanophenyl)-1,1-dimethyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1173] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-oxazol-5-ylphenyl)methyl]pyrrolidine-2-carboxamide;

[1174] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[(4-fluorophenyl)sulfonyl-methyl-amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1175] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-isopropylphenoxy)propyl]pyrrolidine-2-carboxamide;

[1176] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-3,3-difluoro-2-hydroxy-cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1177] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(4,4-difluoro-3-morpholino-butyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1178] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(1,1-dioxothiacyclobutane-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1179] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-pyrrolidone-1-yltetrahydropyran-4-yl)methyl]pyrrolidone-2-carboxamide;

[1180] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(6-isoquinolinylmethyl)pyrrolidine-2-carboxamide;

[1181] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(1,1-dioxo-1,4-thiazin-4-yl)-1-methyl-2-oxo-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1182] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(1,1-dioxothiacyclopentan-2-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1183] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-fluoro-2-(methylsulfonylmethyl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1184] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(6-methoxypyrazin-2-yl)methyl]pyrrolidine-2-carboxamide;

[1185] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4,4-dioxo-1,4-oxathiadin-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1186] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(5-methylimidazo[1,2-a]pyridin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1187] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-[(3,5-dimethylpyrazol-1-yl)methyl]phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1188] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(1,3,4-thiadiazol-2-yl)morpholin-2-yl]methyl]pyrrolidine-2-carboxamide;

[1189] (2S,4R)-N-[2-(4-cyano-2-methyl-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1190] (2S,4R)-N-[(5-bromo-2-chloro-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1191] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2S,3R)-2-(4-fluorophenyl)-1-methyl-pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1192] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(8,8-dioxo-8λ6-thiabicyclo[3.2.1]octane-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1193] (2S,4R)-N-[1-(1,3-benzoxazol-2-yl)-2-phenyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1194] (2S,4R)-N-[1-(1,3-benzothiazo-2-yl)-4-piperidinyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1195] (2S,4R)-N-(3-cyano-1-phenyl-propyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1196] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[1-[5-fluoro-2-(4-hydroxy-1-piperidinyl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1197] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[p-tolyl(1,2,4-triazol-1-yl)methyl]propyl]pyrrolidine-2-carboxamide;

[1198] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-[(1-methyl-4-piperidinyl)oxy]phenyl]methyl]pyrrolidine-2-carboxamide;

[1199] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1200] (2S,4R)-N-[(1R,2R)-2-benzoylaminocyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1201] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[3-(4-fluoro-3-methyl-phenyl)-1,2,4-oxadiazol-5-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1202] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-2-(3-ethoxyphenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1203] (2S,4R)-N-[2-[(5-cyano-2-pyridinyl)oxy]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1204] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[4-(trifluoromethyl)thiazo-2-yl]propyl]pyrrolidine-2-carboxamide;

[1205] N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]ethyl]morpholine-4-carboxamide;

[1206] (2S,4R)-N-[[3-(1-cyanopropoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1207] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1208] (2S,4R)-N-[2-[(4-cyano-2-pyridinyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1209] (2S,4R)-N-[[2-(cyclopentoxy)-3-methoxy-phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1210] (2S,4R)-N-(6-carbamoylspiro[3.3]heptane-2-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1211] (2S,4R)-N-[1-carbamoyl-3-(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1212] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(5-ethyl-3-methyl-isoxazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1213] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(1,1-dioxothiacyclopentan-3-yl)oxyethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1214] (2S,4R)-N-[1-benzyl-2-oxo-2-(1-piperidinyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1215] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2-ethyl-3-oxo-isoxazoline-4-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1216] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[5-methyl-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]ethyl]pyrrolidine-2-carboxamide;

[1217] (2S,4R)-N-[3-[(2-chlorophenyl)sulfonylamino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1218] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(methanesulfonylamino)cyclobutyl]pyrrolidine-2-carboxamide;

[1219] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3R)-1-(4,4,4-trifluorobutyryl)-3-piperidinyl]pyrrolidine-2-carboxamide;

[1220] (2S,4R)-N-[[1-(cyclobutylmethyl)pyrazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1221] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3,3-dimethyl-5-oxo-pyrrolidine-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1222] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(methanesulfonylamino)cyclohexyl]methyl]pyrrolidine-2-carboxamide;

[1223] (2S,4R)-N-[(3-bromo-5-methoxy-phenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1224] (2S,4R)-N-[3-[cyclobutanecarbonyl(cyclopropyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1225] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-phenylpyrazol-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1226] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(4-methoxyphenyl)cyclobutyl]pyrrolidine-2-carboxamide;

[1227] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1,1-dioxo-3,4-dihydro-2H-thiochromene-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1228] 5-Bromo-N-[2-[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]ethyl]pyridine-2-carboxamide;

[1229] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(3S)-isochroman-3-yl]methyl]pyrrolidine-2-carboxamide;

[1230] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(8-fluoroimidozop[1,2-a]pyridin-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1231] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(1-methylimidazol-2-yl)phenyl]methyl]pyrrolidine-2-carboxamide;

[1232] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-ethyl-6-methyl-4-(tetrahydropyran-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1233] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[(1-methylimidazol-2-yl)methyl]-2-oxo-3-piperidinyl]pyrrolidine-2-carboxamide;

[1234] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-methylsulfonylcyclohexyl)pyrrolidine-2-carboxamide;

[1235] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(1S,2R)-1-methylsulfonyl-2-(trifluoromethyl)cyclopropyl]methyl]pyrrolidine-2-carboxamide;

[1236] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[4-(trifluoromethyl)pyrimidin-2-yl]cyclopropyl]pyrrolidine-2-carboxamide;

[1237] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(5-methylisoxazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1238] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(tetrazol-1-yl)propyl]pyrrolidine-2-carboxamide;

[1239] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-morpholinotetrahydropyran-4-yl)pyrrolidine-2-carboxamide;

[1240] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-methylpyrazol-4-yl)-6-oxo-3-piperidinyl]pyrrolidine-2-carboxamide;

[1241] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-pyridinylamino)ethyl]pyrrolidine-2-carboxamide;

[1242] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[(1S,3R)-2,2-difluoro-3-methyl-cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1243] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[(1R,6R)-7,7-difluoro-2-oxabicyclo[4.1.0]heptane-1-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1244] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-(2,6-dimethylmorpholin-4-carbonyl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1245] (2S,4R)-N-[4-cyano-4-(2-pyridyl)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1246] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[2-[2-(methylcarbamoyl)pyrrolidine-1-yl]-2-oxo-ethyl]pyrrolidine-2-carboxamide;

[1247] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]propyl]pyrrolidine-2-carboxamide;

[1248] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-phenyl-1,4-dioxane-2-yl)methyl]pyrrolidine-2-carboxamide;

[1249] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-[isopropyl(methylsulfonyl)amino]propyl]pyrrolidine-2-carboxamide;

[1250] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1-cyclopropyl-3,3,3-trifluoropropyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1251] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)methyl]pyrrolidine-2-carboxamide;

[1252] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4-pyridinyl)azacyclobutane-3-yl]pyrrolidine-2-carboxamide;

[1253] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-hydroxy-2-thiazolyl-5-yl-ethyl)pyrrolidine-2-carboxamide;

[1254] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-isopropoxy-2-methyl-cyclopropyl]pyrrolidine-2-carboxamide;

[1255] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-oxo-2-(2,3,4,5-tetrahydro-1-benzodiazepine] -1-yl)ethyl]pyrrolidine-2-carboxamide;

[1256] (2S,4R)-N-[2-(1-diphenylmethyl-3-hydroxy-azacyclobutane-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1257] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(3-methylpyrazol-1-yl)phenyl]methyl]pyrrolidine-2-carboxamide;

[1258] (2S,4R)-N-[(4-cyclopropyl-5-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1259] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-1-thiazolyl-2-yl-propyl)pyrrolidine-2-carboxamide;

[1260] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(p-tolyl)-1-(2-pyridyl)ethyl]pyrrolidine-2-carboxamide;

[1261] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3,4-difluorophenyl)-(1-methylimidazol-2-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1262] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(3,5-dichlorophenyl)-3-hydroxy-propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1263] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(4-methylpiperazin-1-carbonyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-5-yl]methyl]pyrrolidine-2-carboxamide;

[1264] (2S,4R)-N-[1-(4-benzylmorpholin-2-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1265] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1S,3R)-3-(dimethylamino)cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1266] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropyl]pyrrolidine-2-carboxamide;

[1267] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1S,3R)-3-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1268] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-methylimidazo[1,2-b]pyrazol-7-yl)methyl]pyrrolidine-2-carboxamide;

[1269] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(2S)-1-(p-tolyl)pyrrolidine-2-yl]methyl]pyrrolidine-2-carboxamide;

[1270] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(3,4-dichlorophenyl)pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1271] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-phenylthiocyclobutyl)pyrrolidine-2-carboxamide;

[1272] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4,6-dimethyl-3-pyridinyl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1273] (2S,4R)-N-[2-[benzyl(ethyl)amino]-2-oxo-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1274] (2S,4R)-N-[2-(4-acetamidophenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1275] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-isopropyl-4-methyl-oxazol-5-yl)methyl]pyrrolidine-2-carboxamide;

[1276] (2S,4R)-N-[2-(4-bromoindol-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1277] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(isobutylaminosulfonyl)phenyl]methyl]pyrrolidine-2-carboxamide;

[1278] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-(difluoromethyl)imidazol-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1279] (2S,4R)-N-[4-(4-cyanophenyl)tetrahydropyran-4-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxypyrrolidine-2-carboxamide;

[1280] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(6-methylpyrazin-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1281] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1S,2R)-2-hydroxy-1,2-diphenyl-ethyl]pyrrolidine-2-carboxamide;

[1282] (2S,4R)-N-[2-[benzyl(2-pyridyl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1283] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-methylbenzimidazol-2-yl)-phenyl-methyl]pyrrolidine-2-carboxamide;

[1284] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-hydroxy-1-isopropyl-4-piperidinyl)methyl]pyrrolidine-2-carboxamide;

[1285] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(3-oxopiperazin-1-yl)sulfonylphenyl]methyl]pyrrolidine-2-carboxamide;

[1286] (2S,4R)-N-[3,3-bis(hydroxymethyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1287] (2S,4R)-N-(2-anilino-1,1-dimethyl-2-oxo-ethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1288] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,3-dimethylpyrrolidin-3-yl)-4-hydroxy-pyrrolidin-2-carboxamide;

[1289] (2S,4R)-N-[(1R,2R)-2-(cyclopropylsulfonylamino)cyclohexyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1290] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-oxo-3,5-dihydro-2H-1,5-benzoxazine) -3-yl)pyrrolidine-2-carboxamide;

[1291] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(methylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide;

[1292] (2S,4R)-N-[1-(5-bromo-2-pyridinyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1293] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-methylsulfonylphenyl)-(p-tolyl)methyl]pyrrolidine-2-carboxamide;

[1294] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-1-yl]methyl]pyrrolidine-2-carboxamide;

[1295] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-methyl-4-phenyl-cyclohexyl)pyrrolidine-2-carboxamide;

[1296] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(5-methyl-2-phenyl-oxazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1297] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1298] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydro-4H-cycloheptane[d]isoxazol-3-ylmethyl)pyrrolidine-2-carboxamide;

[1299] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-isopropyltriazol-4-yl)-1-methyl-ethyl]pyrrolidine-2-carboxamide;

[1300] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[3-(trifluoromethyl)phenoxy]butyl]pyrrolidine-2-carboxamide;

[1301] (2S,4R)-N-[2-amino-1-methyl-2-oxo-1-(pyrazol-1-ylmethyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1302] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-methylquininyl-3-yl)pyrrolidine-2-carboxamide;

[1303] (2S,4R)-N-[(7-bromo-4-oxo-pyrido[1,2-a]pyrimidin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1304] (2S,4R)-N-[2-[cyclopropyl(methyl)amino]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1305] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[(2,4-dichlorophenyl)methoxy]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1306] (2S,4R)-N-[3-(5-cyclopropyl-4-phenyl-1,2,4-triazol-3-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1307] (2S,4R)-N-[2-(5-chloroindol-1-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1308] (2S,4R)-N-[(5-bromo-1,3-benzothiazo-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1309] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(4-isobutyl-5-methylthio-1,2,4-triazol-3-yl)propyl]pyrrolidine-2-carboxamide;

[1310] (2S,4R)-N-[2-(2-aminothiazolyl-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1311] (2S,4R)-N-[(4-cyanocyclohexyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1312] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4-hydroxy-6-isopropyl-pyrimidin-2-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1313] (2S,4R)-N-[(2-cyclobutylphenyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1314] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[5-oxo-1-[[2-(trifluoromethyl)phenyl]methyl]pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1315] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(5-fluoro-1-methyl-indol-3-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1316] (2S,4R)-N-(1-benzyl-8-oxa-1-azaspiro[4.5]decane-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1317] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-methoxy-1-naphthyl)ethyl]pyrrolidine-2-carboxamide;

[1318] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-imidazol-1-yl-2-methyl-propyl)pyrrolidine-2-carboxamide;

[1319] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[4-(trifluoromethyl)-2-pyridinyl]ethyl]pyrrolidine-2-carboxamide;

[1320] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-isopropylpyrazole-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1321] (2S,4R)-N-[[5-(3-bromophenyl)oxazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1322] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methylindan-2-yl)pyrrolidine-2-carboxamide;

[1323] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-tetrahydropyran-2-ylprop-2-ynyl)pyrrolidine-2-carboxamide;

[1324] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-indoleazin-2-ylethyl)pyrrolidine-2-carboxamide;

[1325] (4R,5R)-4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-2,2,5-trimethyl-oxazolidine-3-carboxylic acid tert-butyl ester;

[1326] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[4-(dimethylamino)-1-piperidinyl]-2-methyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1327] (2S,4R)-N-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1328] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(3-oxopiperazin-1-yl)ethyl]pyrrolidine-2-carboxamide;

[1329] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(1-methyl-4-oxo-pyrazolo[3,4-d]pyrimidin-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1330] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]pyrrolidine-2-carboxamide;

[1331] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(6-oxo-7-azaspiro[3.5]nonane-9-yl)pyrrolidine-2-carboxamide;

[1332] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[2-(trifluoromethyl)phenyl]cyclobutyl]pyrrolidine-2-carboxamide;

[1333] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(8-oxo-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)methyl]pyrrolidine-2-carboxamide;

[1334] 2-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-4,4-difluoro-2-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester;

[1335] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,3S)-3-(hydroxymethyl)indan-1-yl]pyrrolidine-2-carboxamide;

[1336] (2S,4R)-N-[[(2S,3R)-1-tert-butyl-2-[1-(2-methoxyethyl)pyrazol-4-yl]-5-oxo-pyrrolidine-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1337] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]cyclohexyl]pyrrolidine-2-carboxamide;

[1338] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1S,2S,4R,5R)-4-(hydroxymethyl)-2-bicyclo[3.1.0]hexyl]pyrrolidine-2-carboxamide;

[1339] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-methyl-6-oxo-4-piperidinyl)methyl]pyrrolidine-2-carboxamide;

[1340] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-methyl-4-oxo-6,7-dihydropyrazolo[1,5-a]pyrazin-3-yl)methyl]pyrrolidine-2-carboxamide;

[1341] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-morpholino-2-(2-thienyl)ethyl]pyrrolidine-2-carboxamide;

[1342] (2S,4R)-N-[[2-chloro-6-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1343] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-ethyl-1-(m-tolyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1344] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(3,5-difluorophenyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1345] (2S,4R)-N-[[3-bromo-2-(difluoromethoxy)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1346] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[3-(trifluoromethyl)pyrazol-1-yl]ethyl]pyrrolidine-2-carboxamide;

[1347] (2S,4R)-N-[[5-(4-chloro-2-fluoro-phenyl)-1,2,4-oxadiazol-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1348] (2S,4R)-N-[(1-tert-butylpyrazole-4-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1349] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-7-yl)pyrrolidine-2-carboxamide;

[1350] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl)pyrrolidine-2-carboxamide;

[1351] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3S,4S)-4-(dimethylamino)tetrahydrofuran-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1352] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-methoxy-6-(trifluoromethoxy)phenyl]methyl]pyrrolidine-2-carboxamide;

[1353] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(1-methylpyrrolo-3-yl)sulfonylamino]ethyl]pyrrolidin-2-carboxamide;

[1354] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-pyrimidin-2-yloxypropyl)pyrrolidine-2-carboxamide;

[1355] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(1-methylcyclobutoxy)ethyl]pyrrolidine-2-carboxamide;

[1356] (2S,4R)-N-[[4-(2-amino-2-oxo-ethyl)tetrahydrofuran-2-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1357] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-methoxyethyl)-4,5,6,7-tetrahydroindazol-7-yl]pyrrolidine-2-carboxamide;

[1358] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[[2-(4-fluorophenyl)acetyl]amino]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1359] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-methoxy-6-methyl-2-pyridinyl)methyl]pyrrolidine-2-carboxamide;

[1360] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[5-(4-fluorophenyl)oxazol-2-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1361] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2-ethylsulfinylcyclohexyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1362] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-phenyltriazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[1363] (2S,4R)-N-[2-(4-bromo-2-fluoro-phenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1364] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4-cyclopropyl-1,2,4-triazol-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1365] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(6-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]pyrrolidine-2-carboxamide;

[1366] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[[3-(trifluoromethyl)-2-pyridinyl]amino]ethyl]pyrrolidine-2-carboxamide;

[1367] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-(5-fluoro-2-pyridinyl)cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1368] (2S,4R)-N-[1-(3-cyanophenyl)-1-methyl-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1369] (2S,4R)-N-[2-[1-[(4-chlorophenyl)methyl]imidazol-4-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1370] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[(3-fluorophenyl)methyl]-3-morpholino-3-oxo-propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1371] (2S,4R)-N-[3-(2-cyanoimidazol-1-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1372] (2S,4R)-N-(3-cyano-8-oxaspiro[4.5]decane-4-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1373] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(2-propoxyphenoxy)-3-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[1374] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-fluoro-5-methyl-3-pyridinyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1375] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(o-tolylmethyl)morpholin-2-yl]methyl]pyrrolidine-2-carboxamide;

[1376] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-hydroxy-2-norbornan-2-yl-propyl)pyrrolidine-2-carboxamide;

[1377] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-methyl-1,1-dioxo-thiocyclobutane-3-yl)pyrrolidine-2-carboxamide;

[1378] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-[[2-(hydroxymethyl)pyrrolidine-1-yl]methyl]phenyl]methyl]pyrrolidine-2-carboxamide;

[1379] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(2,6-difluorophenyl)oxetane-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1380] (2S,4R)-N-[[3-[(4-bromophenoxy)methyl]oxetane-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1381] (2S,4R)-N-[1-(cyclopentylmethyl)-4-piperidinyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1382] (2S,4R)-N-[[(3S,5R)-4-benzyl-3-(hydroxymethyl)-5-methylmorpholin-3-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethylbutyryl]-4-hydroxypyrrolidine-2-carboxamide;

[1383] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[4-(3-methylisooxazol-5-yl)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide;

[1384] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2,3,4,5-tetrahydrobenzo[i][1]benzoxazine] -5-yl)pyrrolidine-2-carboxamide;

[1385] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzo[7]arunnel-5-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1386] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[2-(trifluoromethyl)phenyl]cyclopentyl]pyrrolidine-2-carboxamide;

[1387] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3,3,3-trifluoro-1-(o-tolyl)propyl]pyrrolidine-2-carboxamide;

[1388] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4-methoxy-2-naphthyl)ethyl]pyrrolidine-2-carboxamide;

[1389] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[2-(difluoromethoxy)phenyl]pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1390] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[3-(methylaminosulfonyl)anilino]-2-oxo-ethyl]pyrrolidine-2-carboxamide;

[1391] (2S,4R)-N-[3-(benzenesulfonyl)cyclobutyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1392] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1S,3R)-3-(isopropylcarbamoyl)cyclohexyl]pyrrolidine-2-carboxamide;

[1393] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(methoxymethyl)-2-tetrahydropyran-4-yl-ethyl]pyrrolidine-2-carboxamide;

[1394] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1,1-dioxothiazane-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1395] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6,7-dihydro-5H-cyclopentadieno[c]pyridin-4-ylmethyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1396] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[5-(dimethylamino)pyrazin-2-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1397] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-tetrahydronaphth-1-yloxypropyl)pyrrolidine-2-carboxamide;

[1398] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-methoxyethyl)-3-piperidinyl]pyrrolidine-2-carboxamide;

[1399] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-tetrahydropyran-4-yl-4-piperidinyl)methyl]pyrrolidine-2-carboxamide;

[1400] (2S,4R)-N-(1,2-benzoxazol-3-ylmethyl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1401] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3-fluoro-4-pyridinyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1402] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3-cyclopropyl-1,2,4-triazol-4-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1403] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-oxopyrrolidone-3-yl)pyrrolidone-2-carboxamide;

[1404] (2S,4R)-N-[(4-aminopyrimidin-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1405] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-morpholinocyclopentyl)ethyl]pyrrolidine-2-carboxamide;

[1406] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(4-oxothiopheno[3,2-d]pyrimidin-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1407] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-pyrimidin-5-ylethyl)pyrrolidine-2-carboxamide;

[1408] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-tetrahydropyran-4-ylsulfonyl-4-piperidinyl)pyrrolidine-2-carboxamide;

[1409] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydrotetrazol[1,5-a]pyridin-7-yl)pyrrolidine-2-carboxamide;

[1410] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2R,3S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)tetrahydrofuran-3-yl]pyrrolidine-2-carboxamide;

[1411] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,3R)-3-(4-methylpiperazin-1-yl)indan-1-yl]pyrrolidine-2-carboxamide;

[1412] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(7-methyl-8-oxo-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1413] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(3,4-difluorophenyl)-3-methyl-butyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1414] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[4-(dimethylamino)-2-pyridinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1415] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[2-(dimethylamino)-6-methyl-pyrimidin-4-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1416] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-isodihydroindol-2-yl-4-oxo-butyl)pyrrolidine-2-carboxamide;

[1417] (2S,4R)-N-[1-(1-cyclopropyltetrazol-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1418] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-methyloxazol-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1419] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-methyl-2-oxo-3-piperidinyl)pyrrolidine-2-carboxamide;

[1420] (2S,4R)-N-[(1-Cyclopropyl-2-ethyl-benzimidazol-5-yl)methyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1421] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]arunnel-6-yl)pyrrolidine-2-carboxamide;

[1422] (2S,4R)-N-[2-(4-chlorophenyl)-2-(cyclopropylmethoxy)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1423] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-tetrahydrofuran-2-ylcyclobutyl)methyl]pyrrolidine-2-carboxamide;

[1424] (2S,4R)-N-[1-[5-(3-bromophenyl)-1,2,4-oxadiazol-3-yl]propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1425] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4S)-6,8-dimethyl-som-4-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1426] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(isochroman-4-ylmethyl)pyrrolidine-2-carboxamide;

[1427] (2S,4R)-N-[4-(5-chloro-2-thienyl)butyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1428] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-isopropyltetrahydrofuran-3-yl)methyl]pyrrolidine-2-carboxamide;

[1429] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3R)-1-(1,3-dimethyl-2,6-dioxo-pyrimidin-4-yl)pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1430] (2S,4R)-N-[1-(5-chloro-2,3-dihydrobenzofuran-7-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1431] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,2-difluorocyclohexyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1432] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-oxoisodihydroindol-5-yl)methyl]pyrrolidine-2-carboxamide;

[1433] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(1-ethylbenzimidazol-2-yl)ethyl]-4-hydroxypyrrolidine-2-carboxamide;

[1434] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)pyrrolidine-2-carboxamide;

[1435] (2S,4R)-N-[2-(3-bromo-5-chloro-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1436] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(4-methoxy-2-pyridinyl)cyclohexyl]methyl]pyrrolidine-2-carboxamide;

[1437] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(1,2,4-triazol-1-yl)cyclopropyl]methyl]pyrrolidine-2-carboxamide;

[1438] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-spiro[2-oxabicyclo[3.2.0]heptane-7,1'-cyclobutane]-6-yl-pyrrolidine-2-carboxamide;

[1439] (2S,4R)-N-[2-[cyclohexyl(ethyl)aminosulfonyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1440] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-methyl-1,1-dioxo-thiazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[1441] (2S,4R)-N-[1-[1-(4-chlorophenyl)cyclobutyl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1442] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2-fluoro-3-methoxy-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1443] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S,4R,5R)-5-methoxy-5-(trifluoromethyl)norbornan-2-yl]pyrrolidine-2-carboxamide;

[1444] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl)cyclopentyl]pyrrolidine-2-carboxamide;

[1445] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[(2,4-dimethoxyphenyl)methyl]-2-oxo-pyrrolidine-3-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1446] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[4-hydroxy-3-(4-methylpiperazin-1-yl)butyl]pyrrolidine-2-carboxamide;

[1447] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(E)-3-(3-pyridyl)allyl]pyrrolidine-2-carboxamide;

[1448] (2S,4R)-N-(1-Cyclopropyl-5-methyl-pyrrolidine-3-yl)-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1449] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[5-(1-hydroxyethyl)-6-methyl-2-pyridinyl]methyl]pyrrolidine-2-carboxamide;

[1450] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(dimethylamino)-4-methyl-pentyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1451] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1,1-dimethyl-3-(4-methylpiperazin-1-yl)propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1452] (2S,4R)-N-[2-(benzylaminosulfonyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1453] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4-fluorophenyl)-(1-methylpyrazol-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1454] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-(2-methoxyphenyl)isoxazol-5-yl]methyl]pyrrolidine-2-carboxamide;

[1455] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(5-methyltetrazole-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1456] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(phenoxymethyl)cyclobutyl]pyrrolidine-2-carboxamide;

[1457] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1458] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3R,4R)-4-hydroxy-1-isopropyl-pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1459] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-5-ylmethyl)pyrrolidine-2-carboxamide;

[1460] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-4-yl)pyrrolidine-2-carboxamide;

[1461] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(hydroxymethyl)-3,6,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-4-yl]methyl]pyrrolidine-2-carboxamide;

[1462] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(hydroxymethyl)cyclohexyl]-phenyl-methyl]pyrrolidine-2-carboxamide;

[1463] (2S,4R)-N-[1-(5-bromo-2-methoxy-phenyl)-2-hydroxy-ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1464] N-[4-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]phenyl]-N-methyl-pyridine-4-carboxamide;

[1465] (2S,4R)-N-[1-Cyclopropyl-1-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1466] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(5-methyl-2-phenyl-pyrazol-3-yl)ethyl]pyrrolidine-2-carboxamide;

[1467] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-([1,2,4]triazolo[4,3-a]pyrazin-8-yl)-3-piperidinyl]methyl]pyrrolidine-2-carboxamide;

[1468] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-oxo-1,4-dihydro-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide;

[1469] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(4-methylphthalazin-1-yl)-4-piperidinyl]pyrrolidine-2-carboxamide;

[1470] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3,3-dimethyltetrahydropyran-2-yl)methyl]-4-hydroxypyrrolidine-2-carboxamide;

[1471] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-oxo-3-(4-pyrazin-2-ylpiperazin-1-yl)propyl]pyrrolidine-2-carboxamide;

[1472] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2R,3S)-1-methyl-5-oxo-2-(1,3,5-trimethylpyrazol-4-yl)pyrrolidine-3-yl]pyrrolidine-2-carboxamide;

[1473] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-isochroman-7-ylethyl)pyrrolidine-2-carboxamide;

[1474] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1475] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[4-(3-ethyl-1,2,4-oxadiazol-5-yl)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1476] (2S,4R)-N-[(1R,2R)-6-bromo-1-hydroxy-tetrahydronaphthyl-2-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1477] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-1-(1-methylpyrazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1478] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-oxo-1-pyridinyl)-1-phenyl-ethyl]pyrrolidine-2-carboxamide;

[1479] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[4-(difluoromethoxy)cyclohexyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1480] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[4-(trifluoromethyl)-3-thienyl]methyl]pyrrolidine-2-carboxamide;

[1481] (2S,4R)-N-[(3-bromoimidazolo[1,2-a]pyridin-2-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1482] (2S,4R)-N-[(2-benzyl-3-oxo-isodihydroindole-1-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1483] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-imidazo[1,2-a]pyrimidin-2-ylethyl)pyrrolidine-2-carboxamide;

[1484] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-[3-fluoro-5-(trifluoromethyl)phenyl]cyclopropyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1485] (2S,4R)-N-[(1S,2R)-2-tert-butoxy-1-(methylcarbamoyl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1486] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[3-fluoro-4-(2-methylimidazol-1-yl)phenyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1487] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[1-(3-fluorophenyl)pyrazol-3-yl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1488] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[[6-(trifluoromethyl)-2-pyridinyl]oxy]ethyl]pyrrolidine-2-carboxamide;

[1489] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(2,5-dimethylpyrazol-3-yl)oxypropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1490] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(1,2,4-triazol-1-yl)cyclobutyl]pyrrolidine-2-carboxamide;

[1491] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,3-difluorophenyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1492] (2S,4R)-N-[(5-Cyclopropyloxazol-4-yl)methyl]-1-[(2S)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1493] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R)-1-(5-fluoro-3-pyridinyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1494] (2S,4R)-N-[(4-tert-butyl-3-pyridinyl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1495] (2S,4R)-N-(7-chloro-3-yl)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1496] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-oxo-1,3-dihydroimidazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[1497] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[1-(difluoromethylsulfonyl)-4-piperidinyl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1498] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-isopropyl-4,5,6,7-tetrahydroindazole-6-yl)pyrrolidine-2-carboxamide;

[1499] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(3-methylimidazol-4-yl)cyclopropyl]pyrrolidine-2-carboxamide;

[1500] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-quinolinylamino)ethyl]pyrrolidine-2-carboxamide;

[1501] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(1,3-dimethylpyrazol-4-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1502] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-methyl-2-(2-thienyl)-3-piperidinyl]methyl]pyrrolidine-2-carboxamide;

[1503] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(2-methyldihydroindol-1-yl)-2-oxo-ethyl]pyrrolidine-2-carboxamide;

[1504] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(6,6-difluoro-2-bicyclo[3.1.0]hexyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1505] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-hydroxy-5-methoxy-indan-1-yl)methyl]pyrrolidine-2-carboxamide;

[1506] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3,3,3-trifluoro-2-pyrazol-1-yl-propyl)pyrrolidine-2-carboxamide;

[1507] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[2-methoxyethyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1508] 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxylic acid ethyl ester;

[1509] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1510] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylthiazo-4-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1511] (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-thienyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1512] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methyl-1-piperidinyl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1513] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(methanesulfonylaminomethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1514] (2S,4R)-1-[(2S)-2-[4-[2-(1,4-dioxa-9-azaspiro[4.5]decane-9-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1515] (2S,4R)-1-[(2S)-2-[4-(3,4-difluorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1516] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(2,2,6,6-tetramethylmorpholin-4-yl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide;

[1517] 1-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-2-carboxylic acid methyl ester;

[1518] (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethyl-1-piperidinyl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1519] (2S,4R)-1-[(2S)-2-[4-[(4,4-dimethyl-1-piperidinyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1520] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylpiperazin-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1521] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylthiophenyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1522] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydrofuran-3-ylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1523] (2S,4R)-1-[(2S)-2-[4-[[tert-butyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1524] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methyl-1-piperidinyl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1525] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylsulfonylpiperazin-1-yl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1526] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylpiperazin-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1527] (2S,4R)-1-[(2S)-2-[4-(azacycloheptane-1-ylmethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1528] (2S,4R)-1-[(2S)-2-[4-[(diisopropylamino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1529] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methyl-2-piperidinyl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1530] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxopirarin-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1531] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(4-methoxy-1-piperidinyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1532] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methylpyrrolidin-2-yl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methylpyrrolidin-2-carboxamide;

[1533] (2S,4R)-1-[(2S)-2-[4-[2-(4,4-dimethyl-1-piperidinyl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1534] (2S,4R)-1-[(2S)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1535] (2S,4R)-1-[(2S)-2-[4-[3-(3,3-dimethyl-1-piperidinyl)propyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1536] (2S,4R)-1-[(2S)-2-[4-[(2-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1537] (2S,4R)-1-[(2S)-2-[4-[2-(3,3-dimethylazetane-1-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1538] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidin-2-carboxamide;

[1539] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-methyl-2-piperidinyl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1540] (2S,4R)-1-[(2S)-2-[4-[2-(2,2-dimethylmorpholin-4-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1541] (2S,4R)-1-[(2S)-2-[4-(2,6-difluorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1542] (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thioazacycloheptane-4-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1543] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1544] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-methoxy-3-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1545] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-methoxy-2-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1546] (2S,4R)-1-[(2S)-2-[4-[(2-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1547] (2S,4R)-1-[(2S)-2-[4-(3-chlorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1548] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-methylphenoxy)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1549] (2R,4S)-1-[(2S)-2-[4-[2-(4-fluorophenyl)-1-(methylamino)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1550] 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxamide;

[1551] (2S,4R)-1-[(2S)-2-[4-[(4-cyano-1-piperidinyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1552] (2S,4R)-1-[(2S)-2-[4-[(4,4-difluoro-1-piperidinyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1553] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(1-methyl-4-piperidinyl)amino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1554] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(4-methylthiophenyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1555] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-hydroxy-3,3-dimethyl-butyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1556] (2S,4R)-1-[(2S)-2-[4-(2,6-dimethyl-4-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1557] (2R,4S)-1-[(2S)-2-[4-(1-benzylpyrrolidone-3-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidone-2-carboxamide;

[1558] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1-isopropylpyrazol-4-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1559] (2S,4R)-1-[(2S)-2-[4-(4-chloro-2-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1560] (2S,4R)-1-[(2S)-2-[4-[(4-acetylpiperazin-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1561] 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methylamino]benzoic acid;

[1562] (2S,4R)-1-[(2S)-2-[4-(3,5-dichlorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1563] 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl benzoate;

[1564] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-oxo-3-(p-tolyl)propyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1565] 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2-methyl-pyrazole-3-carboxylic acid methyl ester;

[1566] 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-2-carboxylic acid methyl ester;

[1567] 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]benzoate;

[1568] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(2,2,2-trifluoroacetyl)amino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1569] (2S,4R)-1-[(2S)-2-[4-[(ethylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1570] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methyl-1,1-dioxo-1,4-thiazin-4-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1571] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(tetrahydropyran-4-ylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1572] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[2-(morpholinomethyl)imidazol-1-yl]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1573] 4-[1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-1-methyl-ethyl]piperazine-1-carboxylic acid tert-butyl ester;

[1574] (2S,4R)-1-[(2S)-2-[4-(2-chlorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1575] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methylsulfonylethyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1576] (2S,4R)-1-[(2S)-2-[4-[1-(tert-butylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1577] 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperazine-1-carboxylic acid tert-butyl ester;

[1578] (2S,4R)-1-[(2S)-2-[4-(4-amino-3-chloro-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1579] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(4-methylpiperazin-1-yl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1580] (2S,4R)-1-[(2S)-2-[4-[[[cyclohexyl(methyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1581] (2S,4R)-1-[(2S)-2-[4-[(6-aminopurine-9-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1582] (2S,4R)-1-[(2S)-2-[4-[2-(6-azaspiro[3.5]nonane-6-yl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1583] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1-piperidinyl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1584] (2S,4R)-1-[(2S)-2-(4-benzoyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1585] (2S,4R)-1-[(2S)-2-[4-[(4-chloropyrazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1586] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(isodihydroindol-2-ylmethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1587] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[1-(methanesulfonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1588] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxybenzoyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1589] (2S,4R)-1-[(2S)-2-[4-[(3-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1590] (2S,4R)-1-[(2S)-2-[4-[(4-acetylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1591] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-2-carboxylic acid methyl ester;

[1592] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propionate methyl ester;

[1593] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-(1,2,4-triazol-1-yl)ethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1594] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-piperidinyl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1595] (2S,4R)-1-[(2S)-2-[4-(6-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1596] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-hydroxy-3-oxo-pentyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1597] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-oxospiro[3.3]heptane-6-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1598] (2S,4R)-1-[(2S)-2-[4-(4-cyano-3-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1599] (2S,4R)-1-[(2S)-2-[4-(6-fluoro-4-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1600] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1601] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxozyne-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1602] (2S,4R)-1-[(2S)-2-[4-(6-fluoro-2-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1603] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-oxomorpholin-4-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1604] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1605] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(1-hydroxycyclohexyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1606] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[6-(hydroxymethyl)-2-pyridinyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1607] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1608] (2S,4R)-1-[(2S)-2-[4-(4-cyanophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1609] (2S,4R)-1-[(2S)-2-[4-(5-fluoro-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1610] (2S,4R)-1-[(2S)-2-[4-(4-cyclopropylthiazolyl-2-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1611] (2S,4R)-1-[(2S)-2-[4-[(2,5-dimethylpyrrolo-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidin-2-carboxamide;

[1612] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methylthiazo-5-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1613] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-methoxy-3-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1614] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-aminosulfonylpropyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1615] (2S,4R)-1-[(2S)-2-[4-[(dimethylcarbamoylamino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1616] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[[methyl(methylsulfonyl)amino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1617] (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1618] (2S,4R)-1-[(2S)-2-[4-[(cyclopropylsulfonylamino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1619] (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethylpyrazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1620] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-methoxy-2-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1621] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-methylpyrazol-4-yl)oxymethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1622] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-1-pyrrolo-1-yl-ethyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidin-2-carboxamide;

[1623] (2S,4R)-1-[(2S)-2-[4-[4-fluoro-3-(trifluoromethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1624] (2S,4R)-1-[(2S)-2-[4-(2-fluoro-5-methyl-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1625] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-propylpyrazole-4-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1626] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[4-[4-(hydroxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1627] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-oxo-3-phenyl-propyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1628] (2S,4R)-1-[(2S)-2-[4-(5-chloro-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1629] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[1-(hydroxymethyl)cyclobutyl]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1630] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(methylamino)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1631] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[2-(methanesulfonylamino)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1632] (2S,4R)-1-[(2S)-2-[4-[2-(dimethylaminosulfonyl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1633] (2S,4R)-1-[(2S)-2-[4-(2,6-dichlorophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1634] (2S,4R)-1-[(2S)-2-[4-(4,4-dimethyl-3-oxo-pentyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1635] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoic acid;

[1636] 4-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]cyclohexanecarboxylate;

[1637] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-hydroxytetrahydropyran-4-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1638] 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylic acid methyl ester;

[1639] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy(phenyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1640] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(pyrimidin-2-yloxymethyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1641] (2R,4S)-1-[(2S)-2-[4-[(4-tert-butylphenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1642] (2S,4R)-1-[(2S)-2-[4-(2-ethoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1643] (2S,4R)-1-[(2S)-2-[4-(4,4-difluorocyclohexyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1644] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-(2-tetrahydropyran-2-ylethyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1645] (2S,4R)-1-[(2S)-2-[4-(3-bromo-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1646] (2S,4R)-1-[(2S)-2-[4-(2-fluoro-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1647] (2R,4S)-1-[(2S)-2-[4-(1,1-dioxothiazide-3-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1648] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1649] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(N-methylaniline)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide;

[1650] (2S,4R)-1-[(2S)-2-[4-(benzyloxymethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1651] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-toluylsulfonylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1652] (2S,4R)-1-[(2S)-2-[4-[(2-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1653] (2R,4S)-1-[(2S)-2-[4-[4-(4-fluorophenyl)-3-hydroxy-butyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1654] (2S,4R)-1-[(2S)-2-[4-[(3-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1655] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(2-thienylmethylamino)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1656] (2S,4R)-1-[(2S)-2-[4-[2-(2-amino-2-oxo-ethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1657] (2R,4S)-1-[(2S)-2-[4-[(4-chlorophenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1658] (2S,4R)-1-[(2S)-2-[4-[[(3-cyanophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1659] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-(trifluoromethyl)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1660] (2S,4R)-1-[(2S)-2-[4-(6-ethoxy-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1661] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-quinolinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1662] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(3-methoxy-2-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1663] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propionate;

[1664] 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-1-methyl-pyrazole-4-carboxylic acid ethyl ester;

[1665] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]ethyl benzoate;

[1666] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1,3,5-trimethylpyrazol-4-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1667] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2,2-dimethyl-propionate ethyl ester;

[1668] 2-[[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]tetrahydrofuran-2-carboxylic acid ethyl ester;

[1669] [1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]cyclohexyl]carbamate;

[1670] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(thiazol-2-ylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1671] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-oxo-1-pyridinyl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1672] (2S,4R)-1-[(2S)-2-[4-(5,8-dioxaspiro[3,4]octane-2-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1673] (2S,4R)-1-[(2S)-2-[4-(benzoylaminomethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1674] (2S,4R)-1-[(2S)-2-[4-[[(3,4-difluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1675] (2S,4R)-4-hydroxy-1-[(2S)-2-(4-indan-5-yltriazol-1-yl)-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1676] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[2-hydroxy-2-(2-thienyl)propyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1677] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(4-methoxyaniline)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1678] (2S,4R)-1-[(2S)-2-[4-(benzenesulfonylaminomethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1679] (2S,4R)-1-[(2S)-2-[4-[3-[(2-fluoro-3-pyridinyl)oxy]propyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1680] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[1-[4-(hydroxymethyl)phenoxy]propyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1681] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-phenylimidazol-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1682] (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropanecarbonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1683] (2S,4R)-1-[(2S)-2-[4-[2-[2-(2-cyanoethyl)-1,3-dioxolane-2-yl]ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1684] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(methoxymethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1685] (2S,4R)-1-[(2S)-2-[4-[[(2-fluorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1686] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-4,5,6,7-tetrahydroindazol-3-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1687] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylbenzimidazol-2-yl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1688] (2S,4R)-1-[(2S)-2-[4-(5-chloro-2-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1689] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-3-pyridyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1690] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenoxyethyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1691] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[4-(trifluoromethyl)anilino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1692] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[3-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1693] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)cyclohexyloxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1694] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(p-tolylcarbamoylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1695] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[5-[(2-methoxypyrimidin-4-yl)-methyl-amino]-2-methyl-phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1696] (2S,4R)-1-[(2S)-2-[4-[(4,4-dioxo-4λ6-thia-5-azaspiro[2.5]octane-5-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1697] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1698] (2S,4R)-4-hydroxy-1-[(2S)-2-(4-imidazo[1,2-a]pyridin-2-yltriazol-1-yl)-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1699] (2S,4R)-1-[(2S)-2-[4-[2-(difluoromethoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1700] (2S,4R)-1-[(2S)-2-[4-(5-cyclopropyloxazol-4-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1701] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethoxy)-2-pyridyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1702] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(4-pyridylmethylamino)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1703] (2R,4S)-1-[(2S)-2-[4-[(4-fluorophenyl)-hydroxy-methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1704] 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyrrolidine-1-carboxylic acid tert-butyl ester;

[1705] (2S,4R)-1-[(2S)-2-[4-(2-chloro-4-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1706] (2S,4R)-1-[(2S)-2-[4-(1,3-benzothiazo-2-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1707] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-quinolinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1708] (2S,4R)-1-[(2S)-2-[4-[[(2-chlorophenyl)carbamoylamino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1709] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(2-methoxyphenyl)thiomethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1710] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1711] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1712] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[3-hydroxy-3-(2-pyridyl)propyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1713] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-methylbenzimidazol-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1714] N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]pyridine-2-carboxamide;

[1715] (2S,4R)-1-[(2S)-2-[4-(4-tert-butoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1716] N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-6-oxo-1H-pyridine-3-carboxamide;

[1717] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy(p-tolyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1718] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-phenylphenyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1719] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(3-nitrophenyl)carbamoylamino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1720] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylimidazol-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1721] (2S,4R)-1-[(2S)-2-[4-[(5,6-dimethylbenzimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1722] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(phenylcarbamoylamino)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1723] (2S,4R)-1-[(2S)-2-[4-(4,4-difluoro-1-hydroxy-cyclohexyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1724] (2S,4R)-1-[(2S)-2-[4-[(1,1-dioxo-1,4-thiazin-4-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1725] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1726] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[6-(trifluoromethyl)-2-pyridinyl]oxymethyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1727] (2S,4R)-1-[(2S)-2-[4-[[(5-aminopyrazin-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1728] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[[4-(hydroxymethyl)phenyl]thiomethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1729] N-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-2-methylpyrazole-3-carboxamide;

[1730] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(5-oxo-1,4-oxazetane-4-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1731] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(3-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1732] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[4-methyl-3-(phenylcarbamoyl)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1733] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(2-phenylindol-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1734] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-phenylphenyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1735] (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-2,3-difluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1736] (2S,4R)-1-[(2S)-2-[4-[3-[(4-cyanophenyl)sulfonylamino]phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1737] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylsulfonylphenoxy)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1738] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(2-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1739] (2S,4R)-1-[(2S)-2-[4-[2-(ethylamino)-4-pyridyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1740] (2S,4R)-1-[(2S)-2-[4-[1-(cyclopropylsulfonylamino)-1-methyl-ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1741] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(5-isoquinolinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1742] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[methyl(p-toluylsulfonyl)amino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1743] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[4-hydroxy-4-(2-pyridyl)butyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1744] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-4,4-dimethyl-cyclohexyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1745] 7-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-4-azaspiro[2,4]heptane-4-carboxylic acid tert-butyl ester;

[1746] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-aminosulfonylcyclobutyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1747] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[hydroxy-[3-(trifluoromethyl)phenyl]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1748] N-Benzyl-1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazole-4-carboxamide;

[1749] (2S,4R)-1-[(2S)-2-[4-[4-[4-(dimethylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1750] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-methoxy-1-naphthyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1751] (2S,4R)-1-[(2S)-2-[4-[(3,5-difluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1752] (2S,4R)-1-[(2S)-2-[4-[(4-chlorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1753] (2S,4R)-1-[(2S)-2-[4-[3-(benzylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1754] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methylsulfonyl-4-piperidinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1755] (2S,4R)-1-[(2S)-2-[4-[1-(dimethylaminosulfonyl)cyclopropyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1756] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[3-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1757] 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxamide;

[1758] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[6-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1759] (2R,4S)-1-[(2S)-3,3-dimethyl-2-[4-[4-(2,2,2-trifluoro-1-hydroxy-ethyl)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methylpyrrolidine-2-carboxamide;

[1760] (2S,4R)-1-[(2S)-2-[4-[(3-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1761] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[(5-hydroxy-2-oxo-1-piperidinyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1762] (2S,4R)-1-[(2S)-2-[4-(4-acetamidophenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1763] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)benzoyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1764] (2S,4R)-1-[(2S)-2-[4-[(3,5-dimethyl-1,2,4-triazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1765] 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]-1,4-diazacycloheptane-1-carboxylic acid tert-butyl ester;

[1766] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxynorbornan-2-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1767] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxyethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1768] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(4-isopropylcyclohexyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1769] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[[4-(1-hydroxypropyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1770] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-phenyl-2-thienyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1771] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-isoquinolinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1772] 1-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-2-azabicyclo[2.1.1]hexane-2-carboxylic acid tert-butyl ester;

[1773] (2S,4R)-1-[(2S)-2-[4-[4-[4-(cyclobutoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1774] (2S,4R)-1-[(2S)-2-[4-[(1-cyanocyclohexyl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1775] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(2-isopropoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1776] (2S,4R)-1-[(2S)-2-[4-[1-(4-fluorophenyl)cyclopropyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1777] 2-[1-[(1S)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]morpholine-4-carboxylic acid tert-butyl ester;

[1778] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(1-hydroxy-1-methyl-2-phenyl-ethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1779] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(indol-1-ylmethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1780] 3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]azacyclobutane-1-carboxylic acid tert-butyl ester;

[1781] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1782] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(4-isopropoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1783] (2S,4R)-1-[(2S)-2-[4-[[(3-cyanobenzoyl)amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1784] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-isopropoxy-3-pyridinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1785] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(3-hydroxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1786] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-phenylcyclopropyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1787] (2S,4R)-1-[(2S)-2-[4-(3,4-dimethoxyphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1788] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3,4,5-trimethylpyrazol-1-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1789] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-[2-(3-hydroxy-3-methyl-1-piperidinyl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1790] 7-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]dihydroindole-1-carboxylic acid tert-butyl ester;

[1791] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(6-isoquinolinyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1792] (2S,4R)-1-[(2S)-2-[4-(2-chloro-5-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1793] (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-tetrahydronaphth-5-yltriazol-1-yl)butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1794] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[5-(trifluoromethyl)-2-pyridinyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1795] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(isopropylamino)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1796] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[(3-methoxyphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1797] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(3-methylphenoxy)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1798] (2S,4R)-1-[(2S)-2-[4-[[(5-cyanopyrazin-2-yl)-methyl-amino]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1799] (2S,4R)-1-[(2S)-2-[4-[4-[4-(cyclopentoxy)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1800] (2R,4S)-4-hydroxy-1-[(2S)-2-[4-(2-hydroxy-3-phenyl-propyl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1801] (2S,4R)-1-[(2S)-2-[4-[(4-fluorophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1802] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(5-quinolinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1803] (2S,4R)-1-[(2S)-2-[4-(4-ethoxy-3-fluoro-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1804] (2S,4R)-1-[(2S)-3,3-dimethyl-2-(4-quinoxalo-2-yltriazol-1-yl)butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1805] (2S,4R)-1-[(2S)-2-[4-[(4-tert-butylphenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1806] (2S,4R)-1-[(2S)-2-[4-[(3-cyanophenoxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1807] (2S,4R)-4-hydroxy-1-[(2S)-2-(4-isopropenyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1808] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-methyl-4-piperidinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1809] (2R,4S)-1-[(2R)-2-[4-[amino(tetrahydrofuran-2-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1810] (2S,4R)-1-[(2S)-2-[4-(5-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1811] (2S,4R)-1-[(2S)-2-[4-(6-cyano-3-pyridyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1812] (2S,4R)-1-[(2S)-2-[4-[(2-ethylimidazol-1-yl)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1813] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide;

[1814] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(3-methoxyisothiazo-5-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1815] (2S,4R)-1-[(2S)-2-[4-[2-[tert-butyl(methyl)amino]ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1816] (2S,4R)-1-[(2S)-2-[4-(3,3-dimethoxycyclobutyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1817] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-(1H-indol-5-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1818] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(1-aminosulfonylcyclopropyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1819] 4-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]benzoic acid;

[1820] 6-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylic acid;

[1821] 5-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]pyridine-3-carboxylic acid;

[1822] (2R,4S)-4-hydroxy-1-[(2R)-2-[4-[2-hydroxy-2-(2-pyridyl)ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1823] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-oxazol-5-ylethyl)pyrrolidine-2-carboxamide;

[1824] (2S,4R)-1-[(2S)-2-[4-[(4-fluoroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1825] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(6-quinolinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1826] (2S,4R)-1-[(2S)-2-[4-[(4-aminocyclohexyloxy)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1827] 3-Hydroxy-3-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]cyclobutanecarboxylic acid;

[1828] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-oxothiacyclopentan-3-yl)pyrrolidine-2-carboxamide;

[1829] (2S,4R)-1-[(2S)-2-[4-(5-chloro-1,3-dimethyl-pyrazol-4-yl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1830] (2S,4R)-1-[(2S)-2-[4-(3-cyclobutylphenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1831] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(1-oxo-1,4-thiazin-4-yl)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1832] (2S,4R)-N-(2-cyanocyclohexyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1833] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3-hydroxypyrazin-2-yl)methyl]pyrrolidine-2-carboxamide;

[1834] (2S,4R)-4-hydroxy-1-[(2S)-2-[4-[3-(1-hydroxy-1-methyl-ethyl)phenyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1835] (2S,4R)-1-[(2S)-2-[4-[[4-(aminomethyl)phenoxy]methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1836] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyl-5-azaspiro[2.4]heptane-7-yl)pyrrolidine-2-carboxamide;

[1837] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1838] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,5S,6S,7R)-7-hydroxy-6-bicyclo[3.2.0]heptyl]pyrrolidine-2-carboxamide;

[1839] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3,5-dimethyl-4H-isoxazo-5-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1840] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-methyl-5-oxo-pyrrolidine-2-yl)methyl]pyrrolidine-2-carboxamide;

[1841] (2S,4R)-1-[(2S)-2-[4-[(4-chloroanilino)methyl]triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1842] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]ethyl]pyrrolidine-2-carboxamide;

[1843] (2S,4R)-1-[(2S)-2-[4-(4-chloro-3-methoxy-phenyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1844] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(2-methyl-6-quinolinyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1845] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-(trifluoromethyl)-2-pyridyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1846] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-7-yl)pyrrolidine-2-carboxamide;

[1847] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-hydroxy-4-pyridinyl)ethyl]pyrrolidine-2-carboxamide;

[1848] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2R)-2-(2-methylpyrazol-3-yl)cyclopropyl]pyrrolidine-2-carboxamide;

[1849] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-8-yl)pyrrolidine-2-carboxamide;

[1850] (2S,4R)-1-[(2S)-2-[4-(1-benzyloxy-1-methyl-ethyl)triazol-1-yl]-3,3-dimethyl-butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1851] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-oxo-6-azaspiro[3.4]octane-2-yl)pyrrolidine-2-carboxamide;

[1852] (2R,4S)-N-(1-Cyclopropyl-4-methyl-pyrrolidine-3-yl)-1-[(2R)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1853] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-2-azabicyclo[2.2.2]octane-6-yl)pyrrolidine-2-carboxamide;

[1854] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-3,3a,4,5,6,6a-hexahydro-1H-cyclopentadieno[c]pyrrolo-4-yl)pyrrolidine-2-carboxamide;

[1855] 4-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methoxy]benzoic acid;

[1856] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(5-oxo-1,2-dihydropyrazol-3-yl)propyl]pyrrolidine-2-carboxamide;

[1857] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-methyl-6-oxabicyclo[3.2.1]octane-1-yl)pyrrolidine-2-carboxamide;

[1858] 2-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methoxy]pyridine-3-carboxylic acid;

[1859] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[(4-nitrophenoxy)methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1860] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(hydroxymethyl)norbornan-2-yl]pyrrolidine-2-carboxamide;

[1861] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-hydroxy-3-(triazol-1-yl)propyl]pyrrolidine-2-carboxamide;

[1862] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3-(dimethylamino)-2,2-dimethyl-cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1863] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[[(5-methylisoxazol-3-yl)carbamoylamino]methyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1864] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[(2S,4R)-4-methoxytetrahydropyran-2-yl]methyl]pyrrolidine-2-carboxamide;

[1865] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-(3-methylsulfonylphenyl)triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1866] 1-[[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-4-carboxylic acid methyl ester;

[1867] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-([1,2,4]triazolyl[4,3-a]pyridin-6-ylmethyl)pyrrolidine-2-carboxamide;

[1868] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydroisoquinoline-5-yl)pyrrolidine-2-carboxamide;

[1869] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1,1-dioxo-1,2-thiazolidin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1870] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,2S)-2-(1,2,4-triazol-4-yl)cyclopentyl]pyrrolidine-2-carboxamide;

[1871] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-4,5,6,7-tetrahydrobenzotriazol-5-yl)pyrrolidine-2-carboxamide;

[1872] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-4,5,6,7-tetrahydroindazol-4-yl)pyrrolidine-2-carboxamide;

[1873] (2S,4R)-N-[(5-cyclopropyl-2-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1874] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-8-yl)pyrrolidine-2-carboxamide;

[1875] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-hydroxy-2-pyrazol-1-yl-cyclobutyl)pyrrolidine-2-carboxamide;

[1876] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[[2-(methylamino)-2-oxo-ethyl]amino]phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1877] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2-ethylimidazol-1-yl)-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1878] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-methyl-3-(2-methylimidazol-1-yl)propyl]pyrrolidine-2-carboxamide;

[1879] (2S,4R)-N-[(2S,3R)-2-cyclopropyl-6-oxo-3-piperidinyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1880] (2S,4R)-N-[(1R,5R,6R)-3-carbamoyl-6-bicyclo[3.2.0]heptyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1881] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(5-methoxy-1,3-dimethyl-pyrazol-4-yl)methyl]pyrrolidine-2-carboxamide;

[1882] (2S,4R)-N-[(2-tert-butyltetrazole-5-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1883] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,1-dimethyl-2-oxo-2-pyrrolidine-1-yl-ethyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1884] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-isoquinolinylmethyl)pyrrolidine-2-carboxamide;

[1885] 3,3,3-Trifluoro-2-hydroxy-2-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethylpropyl]triazol-4-yl]ethyl propionate;

[1886] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,2-difluorospiro[2,4]heptane-1-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1887] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-methylsulfinylcyclohexyl)pyrrolidine-2-carboxamide;

[1888] (2R,4S)-4-hydroxy-1-[(2R)-2-[4-[2-[3-(hydroxymethyl)-3-methoxy-1-piperidinyl]ethyl]triazol-1-yl]-3,3-dimethyl-butyryl]-N-methyl-pyrrolidine-2-carboxamide;

[1889] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5,6,7,8-tetrahydroquinoline-8-ylmethyl)pyrrolidine-2-carboxamide;

[1890] (2S,4R)-N-[cyclobutyl(2-pyridinyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1891] (2S,4R)-N-[[2-(cyclopropylamino)-4-pyridinyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1892] (2S,4R)-N-[2-(4-cyclopropylpyrimidin-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1893] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(3-pyrimidin-2-yltetrahydrofuran-3-yl)pyrrolidine-2-carboxamide;

[1894] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(4-methoxy-1,1-dioxo-thiapentane-3-yl)pyrrolidine-2-carboxamide;

[1895] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(3-fluoro-2-pyridyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1896] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(hydroxymethyl)-3-(4-pyridyl)propyl]pyrrolidine-2-carboxamide;

[1897] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-5-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1898] (2S,4R)-N-[(5-cyclobutyl-4-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1899] (2S,4R)-N-[(5-cyclopentylisoxazol-3-yl)methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1900] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-isopropoxypyrimidin-4-yl)methyl]pyrrolidine-2-carboxamide;

[1901] (2S,4R)-N-[2-(5-tert-butylisoxazol-3-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1902] (2R,4S)-N-[1-(3-tert-butyl-1,2,4-oxadiazol-5-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1903] (2S,4R)-N-(4-chloro-2,3-dihydrobenzofuran-3-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1904] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(2-oxopyrrolidone-1-yl)pentyl]pyrrolidone-2-carboxamide;

[1905] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(2,2-diethyl-3-methoxy-4-methyl-cyclobutyl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1906] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-phenyl-1,2,4-triazol-3-yl)methyl]pyrrolidine-2-carboxamide;

[1907] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-hydroxy-2-quinolinyl)methyl]pyrrolidine-2-carboxamide;

[1908] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(3,5-dimethoxyisothiazo-4-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1909] (2S,4R)-N-(1-Cyclopropyl-1-methyl-2-phenyl-ethyl)-1-[(2R)-2-(4-Cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1910] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1-methyl-3,4-dihydro-2H-quinolin-3-yl)methyl]pyrrolidine-2-carboxamide;

[1911] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,3-dimethyl-1,1-dioxo-1,2-thiazolidin-3-yl)methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1912] 5-[[[(2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carbonyl]amino]methyl]-N,N-dimethyl-pyridine-2-carboxamide;

[1913] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-oxo-3-(3-pyridinylmethylamino)propyl]pyrrolidine-2-carboxamide;

[1914] (2S,4R)-N-(4-chloro-1,1a,6,6a-tetrahydrocyclopropenzo[a]indene-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1915] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-methylimidazol-2-yl)-4-piperidinyl]pyrrolidine-2-carboxamide;

[1916] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-isopropyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrrolidine-2-carboxamide;

[1917] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-2-(4-fluoro-3-methoxy-phenyl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1918] (2R,4S)-N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methyl-propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1919] (2R,4S)-N-[1-(1-tert-butyl-3-methyl-pyrazol-4-yl)ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1920] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(1-tetrahydrofuran-3-yltriazol-4-yl)ethyl]pyrrolidine-2-carboxamide;

[1921] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[5-(trifluoromethyl)tetrahydrofuran-2-yl]ethyl]pyrrolidine-2-carboxamide;

[1922] (2S,4R)-N-[cyclopropyl-(2,4-difluorophenyl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1923] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R)-5,7-difluorotetrahydronaphth-1-yl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1924] (2R,4S)-N-(3-tert-butoxyspiro[3.3]heptane-1-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1925] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[2-(difluoromethoxy)phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1926] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[3,3-difluoro-1-(imidazol-1-ylmethyl)cyclobutyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1927] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-phenylimidazol-2-yl)ethyl]pyrrolidine-2-carboxamide;

[1928] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(1,5-dimethylindol-3-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1929] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(1-methyl-2-oxo-dihydroindol-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1930] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-methyl-1-([1,2,4]triazolo[4,3-a]pyridin-3-yl)propyl]pyrrolidine-2-carboxamide;

[1931] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1R,2S)-2-(2,3-dihydro-1,4-benzodioxin-5-yl)cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1932] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-(1,1-dioxo-7-oxa-1λ6-thiaspiro[3.5]nonane-3-yl)-4-hydroxy-pyrrolidine-2-carboxamide;

[1933] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2S,3R)-2-(p-tolyl)tetrahydropyran-3-yl]pyrrolidine-2-carboxamide;

[1934] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(5-isopropoxyindan-1-yl)pyrrolidine-2-carboxamide;

[1935] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(2-pyridylmethyl)pyrrolidine-3-yl]methyl]pyrrolidine-2-carboxamide;

[1936] (2S,4R)-N-[3-(6-aminopurine-9-yl)propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1937] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(methanesulfonylaminomethyl)cyclopentyl]pyrrolidine-2-carboxamide;

[1938] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(4-fluoro-1-methyl-benzimidazol-2-yl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1939] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-[(4-fluorophenyl)carbamoyl]cyclopropyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1940] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2S,3R)-2-(1-methylpyrazol-4-yl)-6-oxo-3-piperidinyl]pyrrolidine-2-carboxamide;

[1941] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(3R,4R)-3-(pyrimidin-4-ylamino)tetrahydropyran-4-yl]pyrrolidine-2-carboxamide;

[1942] (2R,4S)-N-[3-amino-1-(6-methoxy-3-pyridinyl)-3-oxo-propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1943] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(4-fluorophenyl)-tetrahydrofuran-2-yl-methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1944] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(1R,3R)-3-morpholinospiro[3.3]heptane-1-yl]pyrrolidine-2-carboxamide;

[1945] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-(2-hydroxycyclohexyl)-4-piperidinyl]pyrrolidine-2-carboxamide;

[1946] (2S,4R)-N-[(1S)-1-(cyclohexylcarbamoyl)-2-methyl-propyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1947] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(2-morpholinothiazo-5-yl)methyl]pyrrolidine-2-carboxamide;

[1948] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(2-pyridyl)spiro[3.3]heptane-2-yl]methyl]pyrrolidine-2-carboxamide;

[1949] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-(2-isopropyl-1,3-benzoxazol-5-yl)ethyl]pyrrolidine-2-carboxamide;

[1950] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-spiro[chroman-2,3'-tetrahydrofuran]-4-yl-pyrrolidine-2-carboxamide;

[1951] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[1-[1-(4-pyridyl)ethyl]-4-piperidinyl]pyrrolidine-2-carboxamide;

[1952] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(4-methyl-2-morpholino-phenyl)methyl]pyrrolidine-2-carboxamide;

[1953] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[2-(methanesulfonylamino)cyclohexyl]methyl]pyrrolidine-2-carboxamide;

[1954] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[1-(methoxymethyl)isocyano-1-yl]methyl]pyrrolidine-2-carboxamide;

[1955] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(1S)-1-[3-[2-(dimethylamino)ethoxy]phenyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1956] (2S,4R)-1-[(2S)-3,3-dimethyl-2-[4-[3-[(2-morpholino-2-oxo-ethyl)amino]phenyl]triazol-1-yl]butyryl]-4-hydroxy-N-methyl-pyrrolidine-2-carboxamide;

[1957] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[(2R,3S)-2-(1-ethylpyrazol-4-yl)tetrahydropyran-3-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1958] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-(2,5-dimethoxyphenyl)-2-hydroxy-1-methyl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1959] 3-[1-[(1S)-1-[(2S,4R)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylic acid tert-butyl ester;

[1960] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-2-(p-toluylsulfonyl)ethyl]pyrrolidine-2-carboxamide;

[1961] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[[3-[methyl(methylsulfonyl)amino]phenyl]methyl]pyrrolidine-2-carboxamide;

[1962] (2R,4S)-N-[1-(1-benzylimidazol-2-yl)propyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1963] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(2,4-dimethylphenyl)-2-imidazol-1-yl-ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1964] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-pyrrolidone-1-yltetrahydronaphth-1-yl)pyrrolidone-2-carboxamide;

[1965] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[[6-(difluoromethoxy)-1,3-benzodioxacyclopenten-5-yl]methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1966] (2S,4R)-N-(7-benzyloxy-6-bicyclo[3.2.0]heptyl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1967] (2S,4R)-N-[2-(2-cyclopentylthiopyrimidin-5-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1968] (2S,4R)-N-[2-(5-chloro-1-oxo-3,4-dihydroisoquinolin-2-yl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1969] (2S,4R)-N-[2-(2-chloro-6-pyrrolidone-1-yl-phenyl)ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidone-2-carboxamide;

[1970] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(8-phenylchroman-4-yl)pyrrolidine-2-carboxamide;

[1971] (2S,4R)-N-[2-[4-(cyclopentanecarbonyl)piperazin-1-yl]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1972] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-dihydroindole-1-ylsulfonylethyl)pyrrolidine-2-carboxamide;

[1973] (2R,4S)-N-[1-[(2-aminothiazolyl-5-yl)methyl]-3-methyl-4-piperidinyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1974] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[2-[(3-fluoro-4-methyl-phenyl)aminosulfonyl]ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1975] (2S,4R)-N-[(2R,3S)-1-cyclopropyl-2-(3-methoxyphenyl)pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1976] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(3,4-dihydro-1H-isoquinoline-2-ylmethyl)-2,2-dimethyl-propyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1977] (2S,4R)-N-[3-(4-chlorophenyl)sulfonylpropyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1978] (2S,4R)-N-[[1-[(3-chlorophenyl)methyl]-2-piperidinyl]methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1979] (2R,4S)-N-[1-[4-(4-chloropyrazol-1-yl)-3-fluoro-phenyl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1980] (2S,4R)-N-(3-bromo-6,7,8,9-tetrahydro-5H-benzo[7]arunen-6-yl)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1981] (2R,4S)-N-[(4-chlorophenyl)-(4-methylmorpholin-2-yl)methyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1982] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[(2,5-dichlorophenyl)-tetrahydrofuran-3-yl-methyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1983] (2S,4R)-N-[[4-tert-butoxy-2-(trifluoromethyl)phenyl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1984] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-methyl-3-[4-(m-tolyl)piperazin-1-yl]propyl]pyrrolidine-2-carboxamide;

[1985] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[2-[methyl-(1-methyl-4-piperidinyl)amino]-1-phenyl-ethyl]pyrrolidine-2-carboxamide;

[1986] (2S,4R)-N-[[1-(4-bromophenyl)pyrazol-4-yl]methyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1987] (2R,4S)-N-[1-[8-chloro-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1988] (2S,4R)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-N-[1-(3,4-dichlorophenyl)-2-(2-pyridyl)ethyl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1989] (2S,4R)-N-[(2R,3S)-2-(4-chloro-3-fluoro-phenyl)-1-isopropyl-5-oxo-pyrrolidine-3-yl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1990] (2S,4R)-N-[2-[(3-bromo-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)amino]ethyl]-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-pyrrolidine-2-carboxamide;

[1991] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[4-[(2-methyltetrazole-5-yl)aminosulfonyl]phenyl]ethyl]pyrrolidine-2-carboxamide;

[1992] 1-[[1-[(1R)-1-[(2R,4S)-4-hydroxy-2-(methylcarbamoyl)pyrrolidine-1-carbonyl]-2,2-dimethyl-propyl]triazol-4-yl]methyl]piperidine-2-carboxylic acid methyl ester;

[1993] (2R,4S)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[3-(3-pyridyl)allyl]pyrrolidine-2-carboxamide;

[1994] (2R,4S)-1-[(2R)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(2-methyl-5-tetrahydrofuran-2-yl-pyrazol-3-yl)pyrrolidine-2-carboxamide;

[1995] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[(7-hydroxypyrazolo[1,5-a]pyrimidin-5-yl)methyl]pyrrolidine-2-carboxamide;

[1996] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[5-(methanesulfonylamino)-2-methoxy-phenyl]pyrrolidine-2-carboxamide;

[1997] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-(1-methyl-4-phenyl-4-piperidinyl)pyrrolidine-2-carboxamide; and

[1998] (2S,4R)-1-[(2S)-2-(4-cyclopropyltriazol-1-yl)-3,3-dimethyl-butyryl]-4-hydroxy-N-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]pyrrolidine-2-carboxamide,

[1999] Or its stereoisomers or tautomers, or medicinal salts of any of the foregoing.

[2000] In some embodiments, this document provides a compound listed in Table 2. In some embodiments, this document provides a stereoisomer or tautomer of a compound listed in Table 2. In some embodiments, this document provides a pharmaceutical salt of a compound listed in Table 2, or a stereoisomer or tautomer thereof.

[2001] Table 2

[2002]

[2003]

[2004]

[2005]

[2006]

[2007] In some embodiments, this document provides a compound listed in Table 2A. In some embodiments, this document provides a stereoisomer or tautomer of a compound listed in Table 2A. In some embodiments, this document provides a pharmaceutical salt of a compound listed in Table 2A, or a stereoisomer or tautomer thereof.

[2008] Table 2A

[2009]

[2010] The compounds described herein can exist in solid or liquid form. In the solid state, the compounds can exist in crystalline or amorphous form or mixtures thereof. Those skilled in the art will understand that pharmaceutical solvates can be formed for crystalline or amorphous compounds. In crystalline solvates, solvent molecules are incorporated into the crystal lattice during crystallization. Solvates can involve non-aqueous solvents, such as, but not limited to, ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or they can involve water as a solvent incorporated into the crystal lattice. Solvates in which water is incorporated into the crystal lattice are generally referred to as “hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing a variable amount of water. Such solvates are included in the subject matter described herein.

[2011] Those skilled in the art will further understand that certain compounds described herein, existing in crystalline form, including their various solvates, can exhibit polymorphism (i.e., the ability to occur in different crystal structures). These different crystalline forms are generally referred to as “polymorphs.” Such polymorphs are the subject of this disclosure. Polymorphs have the same chemical composition but differ in packing, geometric arrangement, and other descriptive properties of their crystalline solid state. Therefore, polymorphs can have different physical properties, such as shape, density, hardness, deformability, stability, and solubility. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which can be used for identification. Those skilled in the art will understand that different polymorphs can be produced, for example, by changing or adjusting the reaction conditions or reagents used to prepare the compounds. For example, changes in temperature, pressure, or solvent can lead to polymorphs. Furthermore, under certain conditions, one polymorph can spontaneously transform into another.

[2012] The compounds described herein, or their pharmaceutical salts, may exist in stereoisomeric forms (e.g., containing one or more asymmetric carbon atoms). Various stereoisomers (enantiomers and diastereomers) and mixtures thereof are included within the scope of the subject matter disclosed herein. Similarly, it should be understood that the compounds or salts described herein may exist in tautomeric forms other than those shown in the formula, and these are also included within the scope of the subject matter disclosed herein. The scope of the subject matter disclosed herein includes mixtures of stereoisomers as well as purified enantiomers or enantiomer / diastereomer-enriched mixtures.

[2013] The subject matter disclosed herein also includes the isotopic labeling of the compounds described herein, but in fact, one or more atoms are replaced by atoms with atomic masses or mass numbers different from those commonly found in nature. Examples of isotopes that can be incorporated into the compounds described herein and their medicinal salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as... 2 H,3 H, 11 C 13 C 14 C 15 N、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 36 Cl、 123 I and 125 I.

[2014] The compounds disclosed herein, and their pharmaceutical salts, containing other isotopes of the aforementioned isotopes and / or other atoms, are within the scope of the subject matter disclosed herein. This document discloses isotopically labeled compounds, such as those doped with radioactive isotopes (e.g., 3 H, 14 Compounds in group C) can be used for drug and / or substrate tissue distribution assays. Tritium compounds are commonly used (i.e.,...). 3 H) and carbon-14 (i.e. 14 C) Isotopes, because they are easy to prepare and detect. 11 C and 18 F isotopes can be used in PET (positron emission tomography), while 125 I- isotopes can be used in SPECT (single-photon emission computed tomography), all of which can be used for brain imaging. Further, heavier isotopes such as deuterium (i.e.,...) can be used... 2 H) substitution can provide certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dose requirements), and is therefore preferred in some cases. Isotope-labeled compounds can generally be prepared by performing the disclosed procedure (by replacing the non-isotope-labeled reagent with an readily available isotope-labeled reagent).

[2015] III. Preparations

[2016] Additionally, this specification provides therapeutic or pharmaceutical compositions comprising an effective amount of at least one of the compounds described herein. Another aspect of this disclosure represents a pharmaceutical composition comprising an effective amount of at least one compound of this disclosure, together with a pharmaceutically effective amount of a carrier, additive or excipient, and optionally an additional bioactive agent.

[2017] In some embodiments, the composition comprises pharmaceutical salts, particularly acid or base addition salts of compounds as described herein. The acids used to prepare pharmaceutical acid addition salts of the aforementioned base compounds include those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochlorides, hydrobromides, hydroiodides, nitrates, sulfates, hydrogen sulfates, phosphates, acid phosphates, acetates, lactates, citrates, acid citrates, tartrates, hydrogen tartrates, succinates, maleates, fumarates, gluconates, sucrose, benzoates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, and bis(hydroxynaphthyl)ate [i.e., 1,1'-methylene-bis(2-hydroxy-3-naphthylcarbamate)] salts, etc.

[2018] Pharmaceutical base addition salts can also be used to produce pharmaceutical salt forms of compounds or derivatives. The chemical bases that can be used as reagents for preparing pharmaceutical base salts of the acidic compounds of this invention are those chemical bases that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to: those base salts derived from such pharmacologically acceptable cations, such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium, zinc, and magnesium); ammonium or water-soluble amine addition salts, such as N-methylglucosamine-(glucosamine); and base salts of lower alkanol ammonium and other pharmaceutical organic amines, etc.

[2019] In some embodiments, the compositions described herein may be administered in single or separate unit doses via oral, parenteral, or topical routes. The range of administration of the compounds can range from continuous (intravenous infusion) to oral administration several times daily (e.g., QID) and may include oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancer), oral, sublingual, and suppository administration, via inhalation spray, rectum, vagina, or via an implanted reservoir, and other routes of administration. Enteric-coated oral tablets may also be used to improve the bioavailability of compounds from oral administration. The most effective dosage form will depend on the pharmacokinetics of the particular agent selected and the severity of disease in the patient. The compounds according to this disclosure may also be used as sprays, mists, or aerosols for intranasal, intratracheal, or pulmonary administration. Therefore, this disclosure also relates to pharmaceutical compositions comprising an effective amount of the compounds according to this disclosure, optionally in combination with a pharmaceutical carrier, additive, or excipient. The compounds according to this disclosure may be administered in an immediate-release, intermediate-release, sustained-release, or controlled-release form. Sustained-release or controlled-release forms are preferably administered orally, but can also be administered via suppositories and transdermal or other topical forms. Intramuscular injection in liposome form can also be used to control or maintain the release of the compound at the injection site.

[2020] Therefore, in one aspect, pharmaceutical formulations of the compounds described herein can be prepared for parenteral administration together with a pharmaceutical parenteral medium in a unit-dose injectable form. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrasheathic, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously.

[2021] The compositions disclosed herein can be formulated using one or more pharmaceutical carriers in a conventional manner and can also be administered as controlled-release formulations. The compounds disclosed herein can be formulated as pharmaceutical compositions according to standard pharmaceutical practice. In this respect, a pharmaceutical composition is provided comprising a compound as described herein in combination with one or more pharmaceutical excipients.

[2022] Typical formulations are prepared by mixing the compounds of this disclosure with excipients such as carriers and / or diluents. Suitable carriers, diluents, and other excipients are well known to those skilled in the art and include materials such as carbohydrates, waxes, water-soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc. The specific carrier, diluent, or excipient used will depend on the manner and purpose of the compound's administration. Other pharmaceutical carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, partially glycerolized mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polypropylene block polymers, polyethylene glycol, and lanolin.

[2023] Solvents are typically selected based on those generally recognized by those skilled in the art as safe for use in mammals (GRAS). Generally, safe solvents are non-toxic aqueous solvents, such as water and other non-toxic solvents that are soluble in or miscible with water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycol (e.g., PEG 400, PEG 300), and mixtures thereof. Acceptable diluents, carriers, excipients, and stabilizers are non-toxic to the receptor at the dosage and concentration used, including buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethyl diammonium chloride; benzalkonium chloride; benzyl chloride; phenol, butanol, or benzyl alcohol; alkyl parabens such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; m-cresol); low molecular weight (less than about 10). (1 residue) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc protein complexes); and / or nonionic surfactants, such as TWEEN. TM PLURONICS TM Or polyethylene glycol (PEG).

[2024] The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, flow aids, processing aids, colorants, sweeteners, flavorings, and other known additives used to display or contribute to the manufacture of the pharmaceutical product. The formulation can be prepared using conventional dissolving and mixing procedures.

[2025] Formulations can be made by mixing the compound with a physiologically acceptable carrier (i.e., a carrier that is non-toxic to the receptor at the dose and concentration used) at ambient temperature, appropriate pH, and desired purity. The pH of the formulation depends primarily on the specific application and concentration of the compound, but can be in the range of about 3 to about 8. Formulations in an acetate buffer at pH 5 are suitable examples.

[2026] Pharmaceutical compositions may be in the form of sterile injectable formulations, such as sterile injectable aqueous or oily suspensions. In particular, formulations intended for in vivo administration must be sterile. Such sterilization is readily achieved through filtration using sterile filter membranes. The suspension can be formulated using suitable dispersants or wetting agents and suspending agents already mentioned above, according to known techniques. Sterile injectable formulations may also be sterile injectable solutions or suspensions in non-toxic, parenteral-acceptable diluents or solvents (such as 1,3-butanediol). Sterile injectable formulations may also be prepared as lyophilized powders. Acceptable media and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile fixed oils are traditionally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can also be used to prepare injectable formulations, as well as natural medicinal oils such as olive oil or castor oil, especially their polyoxyethylene forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as Ph. Helv or similar alcohols.

[2027] Preparations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions that may contain antioxidants, buffers, antibacterial agents and solutes, thereby making the preparation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that may include suspending agents and thickeners.

[2028] The pharmaceutical compositions described herein can be administered orally in any oral dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. In the case of oral tablets, common carriers include lactose and corn starch. Lubricants, such as magnesium stearate, are often also added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When an aqueous suspension is required for oral administration, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners, flavoring agents, or coloring agents may also be added.

[2029] Alternatively, the pharmaceutical compositions described herein can be administered in the form of suppositories for rectal use. These are prepared by mixing the pharmaceutical agent with a suitable, non-irritating excipient that is solid at room temperature but liquid at rectal temperature and thus melts in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[2030] The pharmaceutical compositions described herein can also be applied topically. Suitable topical formulations for each of these areas or organs are readily prepared. Topical application to the lower intestine can be achieved in rectal suppository formulations (see above) or suitable enema formulations. Topically acceptable transdermal patches may also be used.

[2031] For topical application, the pharmaceutical composition can be formulated into a suitable ointment containing an active ingredient suspended or dissolved in one or more carriers. Carriers for topical application of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsified waxes, and water. In certain preferred aspects of this disclosure, the compound can be coated onto a stent to be surgically implanted into a patient to inhibit or reduce the likelihood of stent occlusion in the patient.

[2032] Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or cream containing an active ingredient suspended or dissolved in one or more pharmaceutical carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecyl alcohol, benzyl alcohol, and water.

[2033] For ophthalmic applications, the pharmaceutical composition may be formulated as a micronized suspension in isotonic, pH-adjusted sterile saline, or preferably as a solution in isotonic, pH-adjusted sterile saline, with or without a preservative such as benzyl alkylene chloride. Alternatively, for ophthalmic applications, the pharmaceutical composition may be formulated as an ointment such as petrolatum.

[2034] The pharmaceutical compositions disclosed herein can also be administered via nasal aerosol or inhalation. Such compositions can be prepared, and formulated as solutions in saline solutions, using benzyl alcohol or other suitable preservatives, bioavailability enhancers, fluorocarbons, and / or other commonly used solubilizers or dispersants, according to known techniques in pharmaceutical formulation.

[2035] Pharmaceutical compositions comprising compounds of this disclosure may be formulated, administered, and applied in accordance with good medical practice, i.e., dosage, concentration, schedule, course of treatment, medium, and route of administration. Factors to be considered in this context include the specific disease being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the disease, the site of delivery of the drug, the method of administration, the timing of administration, and other factors known to the practicing physician. The "therapeuticly effective amount" of the compound to be administered will be constrained by such considerations and will be the minimum amount required to prevent, improve, or treat the disease. This amount is preferably below amounts that are toxic to the host or significantly increase the host's susceptibility to undesirable side effects.

[2036] The compounds described herein are formulated into pharmaceutical dosage forms to provide easily controlled drug dosages and enable patients to adhere to prescriptions. Depending on the method of administration, pharmaceutical compositions (or formulations) for administration can be packaged in various ways. Typically, articles for dispensing include containers in which the pharmaceutical formulation is deposited in a suitable form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), pouches, ampoules, plastic bags, metal cylinders, etc. Containers may also include intervention protection components to prevent accidental contact with the packaged contents. Additionally, a label describing the contents of the container is affixed to the container. Appropriate warnings may also be included on the label.

[2037] Formulations can be packaged in single-dose or multi-dose containers, such as sealed ampoules and vials, and can be stored under freeze-dried (lyophilized) conditions, requiring only the addition of a sterile injectable liquid carrier, such as water, before use. Temporary injectable solutions and suspensions are prepared from sterile powders, granules, and tablets of the aforementioned types. Preferred single-dose formulations are those containing the active ingredient at the daily dose or a unit daily sub-dose, or an appropriate fraction thereof, as described above herein.

[2038] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, weight, general health condition, sex, diet, timing of administration, excretion rate, drug combination, as well as the judgment of the treating physician and the severity of the specific disease or condition being treated.

[2039] Patients or subjects requiring therapy with compounds according to this disclosure may be treated by administering an effective amount of a compound according to this disclosure, alone or in combination with other pharmaceutical agents, including pharmaceutical salts, solvates or polymorphs thereof, optionally in a pharmaceutical carrier or diluent.

[2040] The amount of active compound included in the pharmaceutical carrier or diluent is sufficient to deliver a therapeutically effective dose to the patient for the desired indication without causing serious toxicity to the treated patient. Preferred doses of the active compound for the conditions mentioned herein are in the range of about 10 ng / kg to 300 mg / kg daily, preferably 0.1 to 100 mg / kg daily, and more generally 0.5 to about 25 mg / kg of the recipient / patient's body weight. Depending on the foregoing factors, a typical daily dose range may be from about 1 μg / kg to 100 mg / kg or more. A typical local dose range would be 0.01-5% wt / wt in a suitable carrier.

[2041] This compound can be conveniently administered in any suitable unit dosage form, including but not limited to dosage forms containing less than 1 mg, 1 mg to 3000 mg, and preferably 5 to 500 mg of active ingredient per unit dosage form. Oral doses of about 25 to 250 mg are generally convenient.

[2042] The application of the active ingredient preferably achieves a peak plasma concentration of about 0.00001 to 30 mM, more preferably about 0.1 to 30 mM. This can be achieved, for example, by intravenous injection of a solution or formulation of the active ingredient, optionally in a saline or aqueous medium, or as a pill containing the active ingredient. Oral administration is also suitable for active agents that produce effective plasma concentrations.

[2043] The concentration of the active compound in a pharmaceutical composition will depend on the rates of absorption, distribution, inactivation, and excretion of the drug, as well as other factors known to those skilled in the art. It should be noted that dosage values ​​will also vary depending on the severity of the condition to be relieved. It should be further understood that, for any given subject, the specific dosage regimen should be adjusted over time based on individual needs and the professional judgment of the person administering or supervising the administration of the composition, and the concentration ranges listed herein are merely exemplary and not intended to limit the scope or practice of the claimed compositions. The active ingredient may be administered once or divided into multiple smaller doses administered at different time intervals.

[2044] In one embodiment, the active compound is prepared using a carrier that protects the compound from rapid elimination from the body, such as in controlled-release formulations, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art.

[2045] Liposome suspensions can also serve as pharmaceutical carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (the entire contents of which are incorporated herein by reference). For example, a liposome formulation can be prepared by dissolving a suitable lipid (such as stearoylphosphatidylethanolamine, stearoylphosphatidylcholine, arachidonicylphosphatidylcholine, and cholesterol) in an inorganic solvent, followed by evaporation of the inorganic solvent, leaving a thin film of dried lipids on the surface of a container. An aqueous solution of the active compound is then introduced into the container. The container is then freely rotated by hand to release the lipid material from the side of the container and disperse the lipid aggregates, thereby forming a liposome suspension.

[2046] The term "medicinal salt" is used throughout this specification to describe (where applicable) one or more salt forms of the compounds described herein, which are presented to increase the solubility of the compounds in gastric juices of a patient's gastrointestinal tract, thereby promoting the dissolution and bioavailability of the compounds. Where applicable, pharmaceutical salts include those derived from pharmaceutical inorganic or organic bases and acids. Suitable salts include salts derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium, and ammonium salts, and many other acids and bases well known in the pharmaceutical industry. According to this disclosure, sodium and potassium salts are particularly preferred as neutralizing salts of phosphates.

[2047] The subject matter of this invention further provides veterinary compositions comprising at least one active ingredient as defined above and a veterinary carrier. The veterinary carrier is a material that can be used to administer the composition and can be a solid, liquid, or gaseous material that is inert or acceptable in the veterinary field and compatible with the active ingredient. These veterinary compositions can be administered parenterally or via any other intended route.

[2048] IV. Indications and Treatments

[2049] The compounds disclosed herein are intended for therapeutic use. They are also intended for the treatment of diseases or indications associated with VHL activity, such as those described in Zhang et al., J. Med. Chem. 219, 62, 5725-5749, the full text of which is incorporated herein by reference, and particularly with respect to the indications and diseases disclosed therein (including conditions associated with anemia, ischemia, and tumors).

[2050] Typically, the disease or condition to be treated is a hyperproliferative disease, such as cancer. In some embodiments, the compounds disclosed herein can be used to treat cancers involving VHL regulation. In some embodiments, the compounds disclosed herein can be used to treat solid tumors. In some embodiments, solid tumors are breast cancer (such as triple-negative breast cancer), lung cancer, multiple myeloma, or renal cell carcinoma (RCC). In some embodiments, the compounds disclosed herein can be used to treat anemia, including chronic anemia, such as anemia associated with chronic kidney disease, dialysis, and chemotherapy. In some embodiments, the compounds disclosed herein can be used to treat ischemia, including ischemia, stroke, and cardiovascular ischemia.

[2051] In the embodiments, the compound of formula (I) or a pharmaceutical salt thereof, or the compound of formula (II) or a pharmaceutical salt thereof, is used to treat a hyperproliferative disease selected from the group consisting of: breast cancer, lung adenocarcinoma, large cell lung cancer, lung adenosquamous carcinoma, lung squamous cell carcinoma, colon adenocarcinoma, and pancreatic ductal adenocarcinoma.

[2052] V. Products

[2053] On the other hand, this article describes a product (e.g., a kit) containing materials for treating the aforementioned diseases and conditions. This kit may further include a label or instruction leaflet on or associated with the container. The term "packaging insert" is used to refer to instructions typically included in the commercial packaging of a therapeutic product, containing information regarding indications, usage, dosage, administration, contraindications, and / or warnings related to the use of such a therapeutic product.

[2054] Suitable containers include, for example, bottles, vials, syringes, blister packs, etc. A "vial" is a container suitable for containing liquid or lyophilized formulations. In one embodiment, a vial is a disposable vial, such as a 20cc disposable vial with a stopper. Containers can be made from various materials such as glass or plastic.

[2055] Labels or packaging inserts can indicate that the patient to be treated has a condition such as hyperplasia.

[2056] VII. Enumerated Examples

[2057] 1. A compound listed in Table 1-A, Table 1-B or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutical salt thereof.

[2058] 2. A pharmaceutical composition comprising a compound of Table 1-A, Table 1-B or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[2059] 3. A compound listed in Table 1-A, Table 1-B or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutical salt thereof, used in a treatment method.

[2060] 4. The compound according to Example 3, wherein the treatment method comprises administering to a subject in need a therapeutically effective amount of the compound or its stereoisomers or tautomers, or a pharmaceutical salt of any of the foregoing.

[2061] 5. The compound according to Example 4, wherein the subject is a human.

[2062] 6. The compound according to any one of Examples 3 to 5, wherein the treatment method is for treating a disease or indication associated with VHL activity.

[2063] 7. The compound according to Example 6, wherein the disease or indication is a proliferative disorder, anemia, or ischemia.

[2064] 8. The compound according to Example 7, wherein the disease or indication is a hyperproliferative disorder of solid tumors.

[2065] 9. The compound according to Example 8, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

[2066] 10. A method of treating a subject with a disease or indication associated with VHL activity, comprising administering to the subject a therapeutically effective amount of a compound of Table 1-A, Table 1-B or Table 1-C, or a stereoisomer or tautomer thereof, or a pharmaceutical salt thereof.

[2067] 11. The method according to Example 10, wherein the disease or ailment is a hyperproliferative disorder, anemia, or ischemia.

[2068] 12. The method according to Example 11, wherein the disease or indication is a hyperproliferative disorder of solid tumors.

[2069] 13. The method according to Example 12, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma. A kit comprising compounds of Table 1-A, Table 1-B, or Table 1-C, or their stereoisomers or tautomers, or pharmaceutical salts of any of the foregoing, and instructions for use in treating hyperproliferative disorders.

[2070] VII. Examples

[2071] The following synthetic reaction schemes are merely illustrative of some methods that can be used to synthesize the compounds disclosed herein (or their embodiments or aspects). Various modifications to the synthetic reaction schemes can be made with reference to the disclosure contained herein, and suggestions are made to those skilled in the art.

[2072] The starting materials and reagents used to prepare these compounds are generally available from commercial suppliers (such as Aldrich Chemical Co.) or prepared by methods known to those skilled in the art, according to the methods described in the references, such as Fieser and Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, vols. 1–15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, vols. 1–5 and supplements; and Organic Reactions, Wiley & Sons: New York, 1991, vols. 1–40.

[2073] If necessary, the starting materials and intermediates of the synthetic reaction can be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, and chromatography. Conventional methods can be used to characterize these materials, including physical constants and spectral data. The synthetic steps shown in Schemes 1 to 6 can be carried out in any suitable solvent and under any reaction conditions as understood by those skilled in the art.

[2074] Unless otherwise stated, the reactions described herein are preferably carried out under an inert atmosphere, at atmospheric pressure, and at a temperature range of about -78°C to about 150°C, more preferably at a temperature range of about 0°C to about 125°C.

[2075] Although certain exemplary embodiments are depicted and described herein, compounds (or embodiments or aspects thereof) disclosed herein can be prepared using suitable starting materials according to the methods generally described herein and / or by means of methods available to those skilled in the art.

[2076] The following general protocols are used for the preparation of the disclosed compounds, intermediates, and pharmaceutical salts thereof. The disclosed compounds and intermediates can be prepared using standard organic synthesis techniques and commercially available starting materials and reagents. It should be understood that the synthetic processes used to prepare the disclosed compounds and intermediates will depend on the specific substituents present in the compound or intermediate and may require various standard protecting, deprotecting, and transforming steps in organic synthesis, but may not be described in the following general protocols. It should also be understood that any of the steps shown in any of the following general protocols can be used in any chemically feasible combination and sequence to obtain the desired intermediate or disclosed compound. Note that in the following general protocols, R1, R2, L1, and L2 portions are as illustrated elsewhere herein, such as those illustrated by the compounds in Tables 1-A, 1-B, 1-C, and 2, and PG denotes a suitable protecting group.

[2077] Option 1.

[2078]

[2079] Option 2.

[2080]

[2081] Option 3.

[2082]

[2083] Option 4.

[2084]

[2085] Option 5.

[2086]

[2087] Option 6. [...

Claims

1. A compound of formula (I): Or its stereoisomers or tautomers, or pharmaceutical salts of any of the aforementioned compounds, stereoisomers or tautomers, wherein: I)L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; R 2 for i)-O-C6 aryl, optionally substituted by one or more halogens; ii) A 6-membered heterocyclic group, optionally surrounded by one or more -C(O)OC groups. 1-6 Alkyl substitution; iii) 6- to 9-membered heteroaryl groups, substituted by one or more R groups s Replace; where R s It is independently halogenated or C-type each time it appears. 1-12 alkyl; iv) C6 cycloalkyl group, optionally surrounded by one or more -C(O)OC 1-6 Alkyl substitution; or II)L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; R 1 for i)-L 3 -C6 aryl; where L 3 It is O or C(O)NH; and -L 3 The C6 aryl group is optionally substituted with one or more halogenated C6 groups. 1-6 Alkyl substitution; ii)C 6-11 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl; iii) C6 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl; Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5- to 20-membered heteroaryl group is optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl; iv) 5 to 9 yuan heteroaryl groups, optionally surrounded by one or more R s replace, Where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears; or v) A 4- to 10-membered heterocyclic group, optionally surrounded by one or more R s replace, Where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl; Where R s The C mentioned 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl, Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 alkyl.

2. The compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers, or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 for i)-O-C6 aryl, optionally substituted by one or more halogens; ii) A 6-membered heterocyclic group, optionally surrounded by one or more -C(O)OC groups. 1-6 Alkyl substitution; iii) 6- to 9-membered heteroaryl groups, substituted by one or more R groups s Replace; where R s It is independently halogenated or C-type each time it appears. 1-12 alkyl; iv) C6 cycloalkyl group, optionally surrounded by one or more -C(O)OC 1-6 Alkyl substitution.

3. The compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; R 1 for i)-L 3 -C6 aryl; where L 3 It is O or C(O)NH; and -L 3 The C6 aryl group is optionally substituted with one or more halogenated C6 groups. 1-6 Alkyl substitution; ii)C 6-11 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl; iii) C6 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or a 5- to 20-membered heteroaryl group; where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5- to 20-membered heteroaryl group is optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl; iv) 5 to 9 yuan heteroaryl groups, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears; or v) A 4- to 10-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl; Where R s The C mentioned 1-6 Alkyl groups are optionally surrounded by one or more R t replace; Where R t It is C independently each time it appears. 6-20 Aryl, Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

4. The compound according to any one of claims 1 or 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 It is -O-C6 aryl, optionally substituted with one or more halogens.

5. The compound according to any one of claims 1 or 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 It is a 6-membered heterocyclic group, optionally surrounded by one or more -C(O)OC groups. 1-6 Alkyl substitution.

6. The compound according to any one of claims 1 or 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 It is a 6- to 9-membered heteroaryl group, with one or more R s Replace; where R s It is independently halogenated or C-type each time it appears. 1-12 alkyl.

7. The compound according to any one of claims 1 or 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 It is a C6 cycloalkyl group, optionally surrounded by one or more -C(O)OC 1-6 Alkyl substitution.

8. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 -L 3 -C6 aryl; where L 3 It is O or C(O)NH; and -L 3 The C6 aryl group is optionally substituted with one or more halogenated C6 groups. 1-6 Alkyl substitution.

9. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 C 6-11 cycloalkyl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl.

10. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 It is C6 aryl, optionally with one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl; Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5- to 20-membered heteroaryl group is optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl.

11. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 It is a 5- to 9-membered heteroaryl group, optionally surrounded by one or more R groups. s Replace, where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears.

12. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 It is a 4- to 10-membered heterocyclic group, optionally surrounded by one or more R s Replace, where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl; Where R s The C mentioned 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl, Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R u Replace; where R u It is independently halogenated or C each time it appears. 1-6 alkyl.

13. The compound according to claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; and R 2 Choose from the following groups:

14. The compound according to claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 As a key; and R 2 Choose from the following groups:

15. The compound according to claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 1 -R 1 It is methyl; L 2 It is -CH2-; and R 2 Choose from the following groups:

16. The compound according to any one of claims 1 or 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; and R 1 Choose from the following groups:

17. The compound according to claim 1 or claim 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 As a key; and R 1 Choose from the following groups:

18. The compound according to claim 1 or claim 3, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, wherein: L 2 -R 2 It is cyclopropyl; L 1 Choose from the following groups: -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- and -CH(CH2CH3)CH2-; and R 1 Choose from the following groups:

19. The compound of claim 1, or a pharmaceutical salt thereof, wherein the compound is selected from the group consisting of:

20. A compound, or a pharmaceutical salt thereof, wherein said compound is selected from the group consisting of:

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, and one or more pharmaceutical excipients.

22. Use of the compound of any one of claims 1 to 20, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, in the preparation of a medicament for treating a disease or indication associated with VHL activity.

23. The use according to claim 22, wherein the disease or indication is a hyperproliferative disorder, anemia, or ischemia.

24. The use according to claim 23, wherein the hyperproliferative disorder is a solid tumor.

25. The use according to claim 24, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

26. A compound of formula (II): Or its stereoisomers or tautomers, or pharmaceutical salts of any of the aforementioned compounds, stereoisomers or tautomers, wherein: I)L 1 -R 1 It is methyl; L 2 For a bond or -CH2-; R 2 for i)-O-C6 aryl, optionally substituted by one or more halogens; ii) A 6-membered heterocyclic group, optionally surrounded by one or more -C(O)OC groups. 1-6 Alkyl substitution; iii) 6- to 9-membered heteroaryl groups, substituted by one or more R groups s Replace; among them R s It is independently halogenated or C each time it appears. 1-12 alkyl; iv) C6 cycloalkyl group, optionally surrounded by one or more -C(O)OC 1-6 Alkyl substitution; v)-N(CH3)-C6 aryl; iv)-C6 aryl, optionally constituting one or more R s Replace; where R s It is C independently each time it appears. 1-6 Halogenated alkyl; or II)L 2 -R 2 It is cyclopropyl; L 1 For bonds, -CH2-, -CH2CH2-, -CH2CH2CH2-, -C(CH3)2-, -CH(CH2OH)-, -CH(CH2CH3)-, -CH(CH3)CH2- or -CH(CH2CH3)CH2-; R 1 for i)-L 3 -C6 aryl; where L 3 It is O or C(O)NH; and -L 3 The C6 aryl group is optionally substituted with one or more halogenated C6 groups. 1-6 Alkyl substitution; ii)C 6-11 cycloalkyl, optionally with one or more R s Replace; among them R s Each time it appears, it is independently halogenated, 5- to 20-membered heteroaryl, or S(O)C. 1-6 alkyl; iii) C6 aryl, optionally constituting one or more R s Replace; where R s Each time it appears, it is independently halogenated, cyano, or 5- to 20-membered heteroaryl; Where R s The 5- to 20-membered heteroaryl groups have one or more ring atoms independently selected from N and O; and wherein R s The 5- to 20-membered heteroaryl group is optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 1-6 alkyl; iv) 5 to 9 yuan heteroaryl groups, optionally surrounded by one or more R s replace, Where R s Each time it appears, it is independently halogenated, amine, or C. 1-6 Alkyl or C 6-20 Aryl; Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R t Replace; where R t It is halogenated independently each time it appears; or v) A 4- to 10-membered heterocyclic group, optionally surrounded by one or more R s replace, Where R s Each time it appears, it is independently halogenated, oxo-substituted, hydroxyl-substituted, 5- to 20-membered heteroaryl, or C. 6-20 Aryl or C 1-6 alkyl; Where R s The C mentioned 1-6 Alkyl groups are optionally surrounded by one or more R t Replace; where R t It is C independently each time it appears. 6-20 Aryl, Where R s The C mentioned 6-20 Aryl group is optionally bounded by one or more R u Replace; among them R u It is independently halogenated or C-type each time it appears. 1-6 alkyl.

27. A pharmaceutical composition comprising the compound of claim 26, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, and one or more pharmaceutical excipients.

28. Use of the compound of claim 26, or a stereoisomer or tautomer thereof, or a pharmaceutical salt of any of the aforementioned compounds, stereoisomers or tautomers, in the preparation of a medicament for treating a disease or indication associated with VHL activity.

29. The use according to claim 28, wherein the disease or indication is a hyperproliferative disorder, anemia, or ischemia.

30. The use according to claim 29, wherein the hyperproliferative disorder is a solid tumor.

31. The use according to claim 30, wherein the solid tumor is breast cancer, lung cancer, multiple myeloma, or renal cell carcinoma.

Images